SI2797918T1 - Inhibitorji bromodomene - Google Patents
Inhibitorji bromodomene Download PDFInfo
- Publication number
- SI2797918T1 SI2797918T1 SI201231242T SI201231242T SI2797918T1 SI 2797918 T1 SI2797918 T1 SI 2797918T1 SI 201231242 T SI201231242 T SI 201231242T SI 201231242 T SI201231242 T SI 201231242T SI 2797918 T1 SI2797918 T1 SI 2797918T1
- Authority
- SI
- Slovenia
- Prior art keywords
- methyl
- dihydro
- pyrrolo
- pyridin
- phenyl
- Prior art date
Links
- 102000001805 Bromodomains Human genes 0.000 title claims 2
- 108050009021 Bromodomains Proteins 0.000 title claims 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 73
- 150000003839 salts Chemical class 0.000 claims abstract 69
- 206010028980 Neoplasm Diseases 0.000 claims abstract 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 11
- 201000010099 disease Diseases 0.000 claims abstract 10
- 201000011510 cancer Diseases 0.000 claims abstract 8
- 208000030507 AIDS Diseases 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- -1 C 1 -C 6 alkyl Inorganic materials 0.000 claims 129
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 43
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- 125000005466 alkylenyl group Chemical group 0.000 claims 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 20
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical group 0.000 claims 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- 210000004291 uterus Anatomy 0.000 claims 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 201000004253 NUT midline carcinoma Diseases 0.000 claims 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- YQUCNOUQEZHVSC-JMJZKYOTSA-N (2r,3r,4s)-3-acetamido-4-amino-2-(diethylcarbamoyl)-3,4-dihydro-2h-pyran-6-carboxylic acid Chemical group CCN(CC)C(=O)[C@@H]1OC(C(O)=O)=C[C@H](N)[C@H]1NC(C)=O YQUCNOUQEZHVSC-JMJZKYOTSA-N 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- LVPOATBLVBKMSG-UHFFFAOYSA-N 2,2,2-trifluoro-n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxan-3-yloxy)phenyl]ethanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(=O)(=O)CC(F)(F)F)=CC=C1OC1CCCOC1 LVPOATBLVBKMSG-UHFFFAOYSA-N 0.000 claims 1
- BPOKACFPRDOVSU-UHFFFAOYSA-N 2,2,2-trifluoro-n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxan-4-yloxy)phenyl]ethanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(=O)(=O)CC(F)(F)F)=CC=C1OC1CCOCC1 BPOKACFPRDOVSU-UHFFFAOYSA-N 0.000 claims 1
- GLARVCMETZHVMV-UHFFFAOYSA-N 2-[2-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-methylsulfonylphenoxy]benzonitrile Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC=C1C#N GLARVCMETZHVMV-UHFFFAOYSA-N 0.000 claims 1
- XECJYYMTXAGKGT-UHFFFAOYSA-N 2-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenylmethoxyphenyl]acetic acid Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(CC(O)=O)=CC=C1OCC1=CC=CC=C1 XECJYYMTXAGKGT-UHFFFAOYSA-N 0.000 claims 1
- MDFOZSDQSGLITB-UHFFFAOYSA-N 2-[4-(cyclopropylmethoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]acetonitrile Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(CC#N)=CC=C1OCC1CC1 MDFOZSDQSGLITB-UHFFFAOYSA-N 0.000 claims 1
- IVTHHDHMVHZZTA-UHFFFAOYSA-N 2-fluoro-n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxolan-3-yloxy)phenyl]ethanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(=O)(=O)CCF)=CC=C1OC1CCOC1 IVTHHDHMVHZZTA-UHFFFAOYSA-N 0.000 claims 1
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
- CSZKWGRFCCGFSN-UHFFFAOYSA-N 3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxybenzamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(N)=O)=CC=C1OC1=CC=CC=C1 CSZKWGRFCCGFSN-UHFFFAOYSA-N 0.000 claims 1
- VDNCUTQIFKFSCK-UHFFFAOYSA-N 3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxybenzenesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(N)(=O)=O)=CC=C1OC1=CC=CC=C1 VDNCUTQIFKFSCK-UHFFFAOYSA-N 0.000 claims 1
- FIMDIPNIURCNGB-UHFFFAOYSA-N 3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxybenzoic acid Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(O)=O)=CC=C1OC1=CC=CC=C1 FIMDIPNIURCNGB-UHFFFAOYSA-N 0.000 claims 1
- BNSZHEBFMWYDTO-UHFFFAOYSA-N 3-[2-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-methylsulfonylphenoxy]benzonitrile Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC(C#N)=C1 BNSZHEBFMWYDTO-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- BTBMURFSJHIIDB-UHFFFAOYSA-N 4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-n-pyrimidin-2-ylbenzamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(=O)NC=2N=CC=CN=2)=CC=C1OC1=CC=C(F)C=C1F BTBMURFSJHIIDB-UHFFFAOYSA-N 0.000 claims 1
- KERKNWZTDQTZMF-UHFFFAOYSA-N 4-(2-benzylphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC=CC=C1CC1=CC=CC=C1 KERKNWZTDQTZMF-UHFFFAOYSA-N 0.000 claims 1
- BBWOVRAURAFNHT-UHFFFAOYSA-N 4-(2-cycloheptyloxy-5-methylsulfonylphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1CCCCCC1 BBWOVRAURAFNHT-UHFFFAOYSA-N 0.000 claims 1
- IVQKETKHORJLLI-UHFFFAOYSA-N 4-(2-cyclohexyloxy-5-methylsulfonylphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1CCCCC1 IVQKETKHORJLLI-UHFFFAOYSA-N 0.000 claims 1
- ZTTMRIMCXYVCLT-UHFFFAOYSA-N 4-(2-cyclopentyloxy-5-methylsulfonylphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1CCCC1 ZTTMRIMCXYVCLT-UHFFFAOYSA-N 0.000 claims 1
- OXYAAJRMRULKJQ-UHFFFAOYSA-N 4-(2-ethoxy-5-methylsulfonylphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound CCOC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 OXYAAJRMRULKJQ-UHFFFAOYSA-N 0.000 claims 1
- OQVBMGNMXQLMDR-UHFFFAOYSA-N 4-(2-isoquinolin-5-yloxy-5-methylsulfonylphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound N1=CC=C2C(OC3=CC=C(C=C3C3=CN(C(C=4NC=CC=43)=O)C)S(C)(=O)=O)=CC=CC2=C1 OQVBMGNMXQLMDR-UHFFFAOYSA-N 0.000 claims 1
- WLJUSPQUOLPNIO-UHFFFAOYSA-N 4-(2-isoquinolin-7-yloxy-5-methylsulfonylphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=CN=CC2=CC(OC3=CC=C(C=C3C3=CN(C(C=4NC=CC=43)=O)C)S(C)(=O)=O)=CC=C21 WLJUSPQUOLPNIO-UHFFFAOYSA-N 0.000 claims 1
- XZNORKMXRNPIRY-UHFFFAOYSA-N 4-(2-isoquinolin-8-yloxy-5-methylsulfonylphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=NC=C2C(OC3=CC=C(C=C3C3=CN(C(C=4NC=CC=43)=O)C)S(C)(=O)=O)=CC=CC2=C1 XZNORKMXRNPIRY-UHFFFAOYSA-N 0.000 claims 1
- QQROZEZZLHCOJA-UHFFFAOYSA-N 4-(4-bromo-2-methoxyphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound COC1=CC(Br)=CC=C1C1=CN(C)C(=O)C2=C1C=CN2 QQROZEZZLHCOJA-UHFFFAOYSA-N 0.000 claims 1
- RUPFYYBBXZWWBB-UHFFFAOYSA-N 4-(5-amino-2-phenoxyphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(N)=CC=C1OC1=CC=CC=C1 RUPFYYBBXZWWBB-UHFFFAOYSA-N 0.000 claims 1
- YLLSFPFPLLACOF-UHFFFAOYSA-N 4-(5-ethylsulfonyl-2-pyrrolidin-1-ylphenyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1N1CCCC1 YLLSFPFPLLACOF-UHFFFAOYSA-N 0.000 claims 1
- QRAFRSMGWQCTAM-UHFFFAOYSA-N 4-(cyclopropylmethoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-n-phenylbenzenesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(=O)(=O)NC=2C=CC=CC=2)=CC=C1OCC1CC1 QRAFRSMGWQCTAM-UHFFFAOYSA-N 0.000 claims 1
- BNDNNEBBNKRBOY-UHFFFAOYSA-N 4-[2-(1,4-dioxaspiro[4.5]decan-8-yloxy)-5-ethylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OC(CC1)CCC21OCCO2 BNDNNEBBNKRBOY-UHFFFAOYSA-N 0.000 claims 1
- KBOSIPRIXMQRLB-UHFFFAOYSA-N 4-[2-(2,1,3-benzothiadiazol-4-yloxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=CC2=NSN=C2C(OC2=CC=C(C=C2C2=CN(C(C=3NC=CC=32)=O)C)S(C)(=O)=O)=C1 KBOSIPRIXMQRLB-UHFFFAOYSA-N 0.000 claims 1
- XYZOQLOLYPYVPL-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1h-inden-2-yloxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1C2=CC=CC=C2CC1OC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 XYZOQLOLYPYVPL-UHFFFAOYSA-N 0.000 claims 1
- HOJMFSZJWLNURC-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1h-inden-5-yloxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=C2CCCC2=CC(OC2=CC=C(C=C2C2=CN(C(C=3NC=CC=32)=O)C)S(C)(=O)=O)=C1 HOJMFSZJWLNURC-UHFFFAOYSA-N 0.000 claims 1
- LBXQLGRAZRCPAY-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(N2S(CCC2)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F LBXQLGRAZRCPAY-UHFFFAOYSA-N 0.000 claims 1
- OYHGSXRHPUHIOA-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(=O)N2CCS(=O)(=O)CC2)=CC=C1OC1=CC=C(F)C=C1F OYHGSXRHPUHIOA-UHFFFAOYSA-N 0.000 claims 1
- JUFNJPQSSNXUGY-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-(2,3-dihydroindol-1-ylsulfonyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(=O)(=O)N2C3=CC=CC=C3CC2)=CC=C1OC1=CC=C(F)C=C1F JUFNJPQSSNXUGY-UHFFFAOYSA-N 0.000 claims 1
- HAMOOHGDJBQXSK-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-(4-ethylsulfonylpiperazine-1-carbonyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1CN(S(=O)(=O)CC)CCN1C(=O)C(C=C1C=2C=3C=CNC=3C(=O)N(C)C=2)=CC=C1OC1=CC=C(F)C=C1F HAMOOHGDJBQXSK-UHFFFAOYSA-N 0.000 claims 1
- VIUPZUPFISUDFB-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-(ethylsulfonylmethyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(CS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F VIUPZUPFISUDFB-UHFFFAOYSA-N 0.000 claims 1
- XMHPPBWSELNIFB-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)phenyl]-6-methyl-1h-pyrazolo[3,4-c]pyridin-7-one Chemical compound C1=2C=NNC=2C(=O)N(C)C=C1C1=CC(CS(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F XMHPPBWSELNIFB-UHFFFAOYSA-N 0.000 claims 1
- SLEBPXHWVIPWAU-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-(methylsulfonylmethyl)pyridin-3-yl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(CS(C)(=O)=O)=CN=C1OC1=CC=C(F)C=C1F SLEBPXHWVIPWAU-UHFFFAOYSA-N 0.000 claims 1
- KOZYZBOEVUBCLS-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-(morpholine-4-carbonyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(=O)N2CCOCC2)=CC=C1OC1=CC=C(F)C=C1F KOZYZBOEVUBCLS-UHFFFAOYSA-N 0.000 claims 1
- QHBCFQLNMCRKTB-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-(pyrrolidine-1-carbonyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(=O)N2CCCC2)=CC=C1OC1=CC=C(F)C=C1F QHBCFQLNMCRKTB-UHFFFAOYSA-N 0.000 claims 1
- NOVHMCIDCWRHMI-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-(trifluoromethyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(F)(F)F)=CC=C1OC1=CC=C(F)C=C1F NOVHMCIDCWRHMI-UHFFFAOYSA-N 0.000 claims 1
- LOWPRVZGAXOHEG-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-[4-(furan-2-carbonyl)piperazine-1-carbonyl]phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(=O)N2CCN(CC2)C(=O)C=2OC=CC=2)=CC=C1OC1=CC=C(F)C=C1F LOWPRVZGAXOHEG-UHFFFAOYSA-N 0.000 claims 1
- BWKXKRRSDCAKCE-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-ethylsulfonylphenyl]-6-methyl-1h-pyrazolo[3,4-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NN=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F BWKXKRRSDCAKCE-UHFFFAOYSA-N 0.000 claims 1
- LLIKUPXNSZOCEN-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-ethylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F LLIKUPXNSZOCEN-UHFFFAOYSA-N 0.000 claims 1
- BJHAEMIMSJJYRJ-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-2-(1-hydroxyethyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC(C(O)C)=CC=2C=1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F BJHAEMIMSJJYRJ-UHFFFAOYSA-N 0.000 claims 1
- NCKXTEGTJIIARQ-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-2-(hydroxymethyl)-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=C(CO)NC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F NCKXTEGTJIIARQ-UHFFFAOYSA-N 0.000 claims 1
- OSLPNMWKMRZLSV-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-2-[(dimethylamino)methyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC(CN(C)C)=CC=2C=1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F OSLPNMWKMRZLSV-UHFFFAOYSA-N 0.000 claims 1
- GEKBXAMBXDBXGT-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F GEKBXAMBXDBXGT-UHFFFAOYSA-N 0.000 claims 1
- KNJPQUDYBAYKGF-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-2-(4-methylpiperazine-1-carbonyl)-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1CN(C)CCN1C(=O)C(N1)=CC2=C1C(=O)N(C)C=C2C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F KNJPQUDYBAYKGF-UHFFFAOYSA-N 0.000 claims 1
- DFKWVEPWAJIXCK-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-2-(phenoxymethyl)-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=C(COC=3C=CC=CC=3)NC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F DFKWVEPWAJIXCK-UHFFFAOYSA-N 0.000 claims 1
- IPDFZNSXEBIUPN-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-2-[(1,3-thiazol-2-ylamino)methyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=C(CNC=3SC=CN=3)NC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F IPDFZNSXEBIUPN-UHFFFAOYSA-N 0.000 claims 1
- QFNIDPJETIJZKG-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-2-[(4-methylpiperazin-1-yl)methyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1CN(C)CCN1CC(N1)=CC2=C1C(=O)N(C)C=C2C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F QFNIDPJETIJZKG-UHFFFAOYSA-N 0.000 claims 1
- PMFAAQHHEWEOPY-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridine-2-carboxamide Chemical compound C1=2C=C(C(N)=O)NC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F PMFAAQHHEWEOPY-UHFFFAOYSA-N 0.000 claims 1
- LVOYUBDCGVNTOV-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-7-oxo-n-(2,2,2-trifluoroethyl)-1h-pyrrolo[2,3-c]pyridine-2-carboxamide Chemical compound C1=2C=C(C(=O)NCC(F)(F)F)NC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F LVOYUBDCGVNTOV-UHFFFAOYSA-N 0.000 claims 1
- YEJCXNVJTPFUCK-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-n,n,6-trimethyl-7-oxo-1h-pyrrolo[2,3-c]pyridine-2-carboxamide Chemical compound C=1N(C)C(=O)C=2NC(C(=O)N(C)C)=CC=2C=1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F YEJCXNVJTPFUCK-UHFFFAOYSA-N 0.000 claims 1
- GLPRVXBSUHOVMP-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylphenyl]-n-ethyl-6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridine-2-carboxamide Chemical compound C=1N(C)C(=O)C=2NC(C(=O)NCC)=CC=2C=1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F GLPRVXBSUHOVMP-UHFFFAOYSA-N 0.000 claims 1
- DBOQHJHUGXGIPK-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-methylsulfonylpyridin-3-yl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CN=C1OC1=CC=C(F)C=C1F DBOQHJHUGXGIPK-UHFFFAOYSA-N 0.000 claims 1
- IWFKOKYYFVBLCY-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-propan-2-ylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)C(C)C)=CC=C1OC1=CC=C(F)C=C1F IWFKOKYYFVBLCY-UHFFFAOYSA-N 0.000 claims 1
- MFXVYKKHDGOWTG-UHFFFAOYSA-N 4-[2-(2,4-difluorophenoxy)-5-pyrrolidin-1-ylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(=O)(=O)N2CCCC2)=CC=C1OC1=CC=C(F)C=C1F MFXVYKKHDGOWTG-UHFFFAOYSA-N 0.000 claims 1
- KTYSSOFCJMDCDE-UHFFFAOYSA-N 4-[2-(2,5-difluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC(F)=CC=C1F KTYSSOFCJMDCDE-UHFFFAOYSA-N 0.000 claims 1
- NQCNBSQOHXBQCR-UHFFFAOYSA-N 4-[2-(2-chlorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC=C1Cl NQCNBSQOHXBQCR-UHFFFAOYSA-N 0.000 claims 1
- WULUMURXICTAGJ-UHFFFAOYSA-N 4-[2-(2-cyclopropylethoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OCCC1CC1 WULUMURXICTAGJ-UHFFFAOYSA-N 0.000 claims 1
- LKNFPRWDLAYZTE-UHFFFAOYSA-N 4-[2-(2-fluoro-5-methylphenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound CC1=CC=C(F)C(OC=2C(=CC(=CC=2)S(C)(=O)=O)C=2C=3C=CNC=3C(=O)N(C)C=2)=C1 LKNFPRWDLAYZTE-UHFFFAOYSA-N 0.000 claims 1
- IPNIOMPUYUHGOT-UHFFFAOYSA-N 4-[2-(2-fluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC=C1F IPNIOMPUYUHGOT-UHFFFAOYSA-N 0.000 claims 1
- IDSAVRDLNFLTSB-UHFFFAOYSA-N 4-[2-(2-methoxyphenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound COC1=CC=CC=C1OC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 IDSAVRDLNFLTSB-UHFFFAOYSA-N 0.000 claims 1
- YNAXGMFUTMAGGX-UHFFFAOYSA-N 4-[2-(3,4-difluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C(F)=C1 YNAXGMFUTMAGGX-UHFFFAOYSA-N 0.000 claims 1
- NYZHZGSMYHIIJD-UHFFFAOYSA-N 4-[2-(3,5-difluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC(F)=CC(F)=C1 NYZHZGSMYHIIJD-UHFFFAOYSA-N 0.000 claims 1
- OJIGSUHIIHQFRK-UHFFFAOYSA-N 4-[2-(3-aminophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC(N)=C1 OJIGSUHIIHQFRK-UHFFFAOYSA-N 0.000 claims 1
- NXLMESONDPOGFK-UHFFFAOYSA-N 4-[2-(3-chloro-2-fluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC(Cl)=C1F NXLMESONDPOGFK-UHFFFAOYSA-N 0.000 claims 1
- NPXWTTDBBPQVFM-UHFFFAOYSA-N 4-[2-(3-chlorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC(Cl)=C1 NPXWTTDBBPQVFM-UHFFFAOYSA-N 0.000 claims 1
- UOJZOKVTYLELME-UHFFFAOYSA-N 4-[2-(3-fluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC(F)=C1 UOJZOKVTYLELME-UHFFFAOYSA-N 0.000 claims 1
- CPPVPVMEYLNEAH-UHFFFAOYSA-N 4-[2-(4,4-difluorocyclohexyl)oxy-5-ethylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OC1CCC(F)(F)CC1 CPPVPVMEYLNEAH-UHFFFAOYSA-N 0.000 claims 1
- CUAFFZTZZKBUGM-UHFFFAOYSA-N 4-[2-(4-chloro-3-fluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(Cl)C(F)=C1 CUAFFZTZZKBUGM-UHFFFAOYSA-N 0.000 claims 1
- CFKXAZZXTAUEQK-UHFFFAOYSA-N 4-[2-(4-chlorobenzoyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC=CC=C1C(=O)C1=CC=C(Cl)C=C1 CFKXAZZXTAUEQK-UHFFFAOYSA-N 0.000 claims 1
- DMIUKRLJLGLETK-UHFFFAOYSA-N 4-[2-(4-chlorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(Cl)C=C1 DMIUKRLJLGLETK-UHFFFAOYSA-N 0.000 claims 1
- GMZLXOWSCAYGAF-UHFFFAOYSA-N 4-[2-(4-fluoroanilino)-5-(methylsulfonylmethyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(CS(C)(=O)=O)=CC=C1NC1=CC=C(F)C=C1 GMZLXOWSCAYGAF-UHFFFAOYSA-N 0.000 claims 1
- JVYANJDBSZLINI-UHFFFAOYSA-N 4-[2-(4-fluoroanilino)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1NC1=CC=C(F)C=C1 JVYANJDBSZLINI-UHFFFAOYSA-N 0.000 claims 1
- MZIDCCPICWCACE-UHFFFAOYSA-N 4-[2-(4-fluorophenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1 MZIDCCPICWCACE-UHFFFAOYSA-N 0.000 claims 1
- KSVUZNQZHYBWIR-UHFFFAOYSA-N 4-[2-(5-fluoro-2-methylphenoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound CC1=CC=C(F)C=C1OC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 KSVUZNQZHYBWIR-UHFFFAOYSA-N 0.000 claims 1
- YIIWYSIHAIFNCE-UHFFFAOYSA-N 4-[2-(cyclobutylmethoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OCC1CCC1 YIIWYSIHAIFNCE-UHFFFAOYSA-N 0.000 claims 1
- GROOZCZSDDSNFT-UHFFFAOYSA-N 4-[2-(cyclohexylamino)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1NC1CCCCC1 GROOZCZSDDSNFT-UHFFFAOYSA-N 0.000 claims 1
- KYKIURODSVAASY-UHFFFAOYSA-N 4-[2-(cyclohexylmethoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OCC1CCCCC1 KYKIURODSVAASY-UHFFFAOYSA-N 0.000 claims 1
- MOLZQZCLRXBCMM-UHFFFAOYSA-N 4-[2-(cyclopentylmethoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OCC1CCCC1 MOLZQZCLRXBCMM-UHFFFAOYSA-N 0.000 claims 1
- BMZKXDVTPUCPKE-UHFFFAOYSA-N 4-[2-(cyclopropylamino)-5-ethylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1NC1CC1 BMZKXDVTPUCPKE-UHFFFAOYSA-N 0.000 claims 1
- DCVVAEQXFNLHJR-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C=2CCNCC=2)=CC=C1OCC1CC1 DCVVAEQXFNLHJR-UHFFFAOYSA-N 0.000 claims 1
- MMMAOGOGNTXXRN-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-(1-methylpyrazol-4-yl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=NN(C)C=C1C(C=C1C=2C=3C=CNC=3C(=O)N(C)C=2)=CC=C1OCC1CC1 MMMAOGOGNTXXRN-UHFFFAOYSA-N 0.000 claims 1
- SWUKTDMWRNJWHJ-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-(3-fluorophenyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C=2C=C(F)C=CC=2)=CC=C1OCC1CC1 SWUKTDMWRNJWHJ-UHFFFAOYSA-N 0.000 claims 1
- SLIQOPPYJKGTPA-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-(4-hydroxypiperidin-1-yl)sulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(=O)(=O)N2CCC(O)CC2)=CC=C1OCC1CC1 SLIQOPPYJKGTPA-UHFFFAOYSA-N 0.000 claims 1
- OMJNRHJWPMTRLF-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-(6-fluoropyridin-3-yl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C=2C=NC(F)=CC=2)=CC=C1OCC1CC1 OMJNRHJWPMTRLF-UHFFFAOYSA-N 0.000 claims 1
- OXZOLXBCNJCKIO-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-(pyrrolidin-1-ylmethyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C(C(=CC=1)OCC2CC2)=CC=1CN1CCCC1 OXZOLXBCNJCKIO-UHFFFAOYSA-N 0.000 claims 1
- MDMXEIISEDTCCN-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-(trifluoromethylsulfonyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(=O)(=O)C(F)(F)F)=CC=C1OCC1CC1 MDMXEIISEDTCCN-UHFFFAOYSA-N 0.000 claims 1
- GFLRSOLIMCICHB-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-[3-(dimethylamino)pyrrolidin-1-yl]sulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1C(N(C)C)CCN1S(=O)(=O)C(C=C1C=2C=3C=CNC=3C(=O)N(C)C=2)=CC=C1OCC1CC1 GFLRSOLIMCICHB-UHFFFAOYSA-N 0.000 claims 1
- DGBXTQXULBPDEX-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-ethylsulfonylphenyl]-6-methyl-1H-pyrrolo[2,3-d]pyridazin-7-one Chemical compound N=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OCC1CC1 DGBXTQXULBPDEX-UHFFFAOYSA-N 0.000 claims 1
- ODOLRHQJQABEIL-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-ethylsulfonylphenyl]-6-methyl-1h-pyrazolo[3,4-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NN=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OCC1CC1 ODOLRHQJQABEIL-UHFFFAOYSA-N 0.000 claims 1
- CRIJGBUXORSEFD-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-ethylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OCC1CC1 CRIJGBUXORSEFD-UHFFFAOYSA-N 0.000 claims 1
- ZHEYWIFYZNAPLC-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-fluorophenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(F)=CC=C1OCC1CC1 ZHEYWIFYZNAPLC-UHFFFAOYSA-N 0.000 claims 1
- COSBTRPLBVPWCS-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OCC1CC1 COSBTRPLBVPWCS-UHFFFAOYSA-N 0.000 claims 1
- LAGYNOPMJOWIIO-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-morpholin-4-ylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(=O)(=O)N2CCOCC2)=CC=C1OCC1CC1 LAGYNOPMJOWIIO-UHFFFAOYSA-N 0.000 claims 1
- ILENDFBZDQQQCC-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-6-methylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C=1C(C)=CC=CC=1OCC1CC1 ILENDFBZDQQQCC-UHFFFAOYSA-N 0.000 claims 1
- PANKYEYISTWOJG-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)-5-(methylsulfonylmethyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(CS(C)(=O)=O)=CC=C1NCC1CC1 PANKYEYISTWOJG-UHFFFAOYSA-N 0.000 claims 1
- IZROWPSXGTUCLB-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)-5-(trifluoromethylsulfonyl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(=O)(=O)C(F)(F)F)=CC=C1NCC1CC1 IZROWPSXGTUCLB-UHFFFAOYSA-N 0.000 claims 1
- ZQRYCQNBELIIBM-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)-5-ethylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1NCC1CC1 ZQRYCQNBELIIBM-UHFFFAOYSA-N 0.000 claims 1
- GOKKCJVNYOPUCZ-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1NCC1CC1 GOKKCJVNYOPUCZ-UHFFFAOYSA-N 0.000 claims 1
- CGKGBZCNRSWWRS-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)-5-propan-2-ylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)C(C)C)=CC=C1NCC1CC1 CGKGBZCNRSWWRS-UHFFFAOYSA-N 0.000 claims 1
- MRCQYKPXQDZOEG-UHFFFAOYSA-N 4-[2-(cyclopropylmethylamino)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC=CC=C1NCC1CC1 MRCQYKPXQDZOEG-UHFFFAOYSA-N 0.000 claims 1
- HFOXMNKPXPRCDI-UHFFFAOYSA-N 4-[2-[(2,2-difluorocyclopropyl)methoxy]-5-ethylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OCC1CC1(F)F HFOXMNKPXPRCDI-UHFFFAOYSA-N 0.000 claims 1
- KPUTWNZRZOAMKV-UHFFFAOYSA-N 4-[2-[(4-chlorophenyl)-hydroxymethyl]phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC=CC=C1C(O)C1=CC=C(Cl)C=C1 KPUTWNZRZOAMKV-UHFFFAOYSA-N 0.000 claims 1
- ZCRNJUAJQLCRQI-UHFFFAOYSA-N 4-[2-[2-(2-hydroxyethyl)phenoxy]-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC=C1CCO ZCRNJUAJQLCRQI-UHFFFAOYSA-N 0.000 claims 1
- MFFOBQULPKQZGP-UHFFFAOYSA-N 4-[2-[2-chloro-5-(trifluoromethyl)phenoxy]-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC(C(F)(F)F)=CC=C1Cl MFFOBQULPKQZGP-UHFFFAOYSA-N 0.000 claims 1
- RIDRFOBOVKJVAD-UHFFFAOYSA-N 4-[2-[2-fluoro-5-(trifluoromethyl)phenoxy]-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC(C(F)(F)F)=CC=C1F RIDRFOBOVKJVAD-UHFFFAOYSA-N 0.000 claims 1
- AKGNSNYGPWWAAI-UHFFFAOYSA-N 4-[2-[3-(dimethylamino)phenoxy]-5-methylsulfonylphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound CN(C)C1=CC=CC(OC=2C(=CC(=CC=2)S(C)(=O)=O)C=2C=3C=CNC=3C(=O)N(C)C=2)=C1 AKGNSNYGPWWAAI-UHFFFAOYSA-N 0.000 claims 1
- IDLWOORAOHFVHT-UHFFFAOYSA-N 4-[4-(ethylsulfonylamino)-2-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenoxy]benzamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(C(N)=O)C=C1 IDLWOORAOHFVHT-UHFFFAOYSA-N 0.000 claims 1
- VRKKIBAWLDCPDL-UHFFFAOYSA-N 4-[4-ethylsulfonyl-2-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenoxy]benzonitrile Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OC1=CC=C(C#N)C=C1 VRKKIBAWLDCPDL-UHFFFAOYSA-N 0.000 claims 1
- SUFWHYCYTPCUQN-UHFFFAOYSA-N 4-[5-(2-hydroxyethyl)-2-phenylmethoxyphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(CCO)=CC=C1OCC1=CC=CC=C1 SUFWHYCYTPCUQN-UHFFFAOYSA-N 0.000 claims 1
- FXYNOBGMMQKXPH-UHFFFAOYSA-N 4-[5-(benzenesulfonyl)-2-(cyclopropylmethoxy)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(=O)(=O)C=2C=CC=CC=2)=CC=C1OCC1CC1 FXYNOBGMMQKXPH-UHFFFAOYSA-N 0.000 claims 1
- DUDHRJRBABPTMZ-UHFFFAOYSA-N 4-[5-(benzenesulfonylmethyl)-2-(2,4-difluorophenoxy)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C(C(=CC=1)OC=2C(=CC(F)=CC=2)F)=CC=1CS(=O)(=O)C1=CC=CC=C1 DUDHRJRBABPTMZ-UHFFFAOYSA-N 0.000 claims 1
- SFDROCHFRBBUBF-UHFFFAOYSA-N 4-[5-(hydroxymethyl)-2-phenoxyphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(CO)=CC=C1OC1=CC=CC=C1 SFDROCHFRBBUBF-UHFFFAOYSA-N 0.000 claims 1
- OQZQYJKHUSUKQI-UHFFFAOYSA-N 4-[5-(methanesulfonamido)-2-phenoxyphenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-d]pyridazine-2-carboxamide Chemical compound C1=2C=C(C(N)=O)NC=2C(=O)N(C)N=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 OQZQYJKHUSUKQI-UHFFFAOYSA-N 0.000 claims 1
- FHQSOCYIXBWLOM-UHFFFAOYSA-N 4-[5-(methanesulfonamido)-2-phenoxyphenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-d]pyridazine-2-carboxylic acid Chemical compound C1=2C=C(C(O)=O)NC=2C(=O)N(C)N=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 FHQSOCYIXBWLOM-UHFFFAOYSA-N 0.000 claims 1
- UXNPIJWXHLLNAH-UHFFFAOYSA-N 4-[5-(methanesulfonamido)-2-phenoxyphenyl]-6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridine-2-carboxamide Chemical compound C1=2C=C(C(N)=O)NC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 UXNPIJWXHLLNAH-UHFFFAOYSA-N 0.000 claims 1
- WUHSWYDCMKHYRT-UHFFFAOYSA-N 4-[5-(methanesulfonamido)-2-phenoxyphenyl]-6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridine-2-carboxylic acid Chemical compound C1=2C=C(C(O)=O)NC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 WUHSWYDCMKHYRT-UHFFFAOYSA-N 0.000 claims 1
- USPHDQMFECQFEU-UHFFFAOYSA-N 4-[5-amino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-1H-pyrrolo[2,3-d]pyridazin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)N=C1C1=CC(N)=CC=C1OC1=CC=C(F)C=C1F USPHDQMFECQFEU-UHFFFAOYSA-N 0.000 claims 1
- VLPSMCQEXOQJNL-UHFFFAOYSA-N 4-[5-cyclopropylsulfonyl-2-(2,4-difluorophenoxy)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(=O)(=O)C2CC2)=CC=C1OC1=CC=C(F)C=C1F VLPSMCQEXOQJNL-UHFFFAOYSA-N 0.000 claims 1
- AFMAJPSMWGELJQ-UHFFFAOYSA-N 4-[5-ethylsulfonyl-2-(1-methylpiperidin-4-yl)oxyphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OC1CCN(C)CC1 AFMAJPSMWGELJQ-UHFFFAOYSA-N 0.000 claims 1
- NBRRDAGQJCKBBQ-UHFFFAOYSA-N 4-[5-ethylsulfonyl-2-(4-hydroxycyclohexyl)oxyphenyl]-6-methyl-1H-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OC1CCC(O)CC1 NBRRDAGQJCKBBQ-UHFFFAOYSA-N 0.000 claims 1
- YUJPYONFHKXOKX-UHFFFAOYSA-N 4-[5-ethylsulfonyl-2-(4-methylpiperazin-1-yl)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1N1CCN(C)CC1 YUJPYONFHKXOKX-UHFFFAOYSA-N 0.000 claims 1
- DWLSZNXDPVERQM-UHFFFAOYSA-N 4-[5-ethylsulfonyl-2-(4-oxocyclohexyl)oxyphenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OC1CCC(=O)CC1 DWLSZNXDPVERQM-UHFFFAOYSA-N 0.000 claims 1
- XZTLXZNAZJAIRH-UHFFFAOYSA-N 4-[5-ethylsulfonyl-2-(thian-4-yloxy)phenyl]-6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1OC1CCSCC1 XZTLXZNAZJAIRH-UHFFFAOYSA-N 0.000 claims 1
- TUCDGNXHLJTDBX-UHFFFAOYSA-N 4-[[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxyphenyl]methylamino]-4-oxobutanoic acid Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(CNC(=O)CCC(O)=O)=CC=C1OC1=CC=CC=C1 TUCDGNXHLJTDBX-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- FNTQVTSIICHTJX-UHFFFAOYSA-N 6-methyl-4-(2-phenoxyphenyl)-1H-pyrrolo[2,3-d]pyridazin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)N=C1C1=CC=CC=C1OC1=CC=CC=C1 FNTQVTSIICHTJX-UHFFFAOYSA-N 0.000 claims 1
- NUAFIMXCNWRSMX-UHFFFAOYSA-N 6-methyl-4-(2-phenoxyphenyl)-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC=CC=C1OC1=CC=CC=C1 NUAFIMXCNWRSMX-UHFFFAOYSA-N 0.000 claims 1
- SSXDUWNQVRCJCW-UHFFFAOYSA-N 6-methyl-4-(2-phenoxyphenyl)-2-phenyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=C(C=3C=CC=CC=3)NC=2C(=O)N(C)C=C1C1=CC=CC=C1OC1=CC=CC=C1 SSXDUWNQVRCJCW-UHFFFAOYSA-N 0.000 claims 1
- WDEJDKDRTOLRBA-UHFFFAOYSA-N 6-methyl-4-(2-phenylphenyl)-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC=CC=C1C1=CC=CC=C1 WDEJDKDRTOLRBA-UHFFFAOYSA-N 0.000 claims 1
- QMPNYTDAJDKBAZ-UHFFFAOYSA-N 6-methyl-4-(5-methylsulfonyl-2-naphthalen-1-yloxyphenyl)-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=CC=C2C(OC3=CC=C(C=C3C3=CN(C(C=4NC=CC=43)=O)C)S(C)(=O)=O)=CC=CC2=C1 QMPNYTDAJDKBAZ-UHFFFAOYSA-N 0.000 claims 1
- CGASLGCHTWREOZ-UHFFFAOYSA-N 6-methyl-4-(5-methylsulfonyl-2-phenoxyphenyl)-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC=C1 CGASLGCHTWREOZ-UHFFFAOYSA-N 0.000 claims 1
- LPYJHGOLVXMURG-UHFFFAOYSA-N 6-methyl-4-(5-methylsulfonyl-2-pyridin-3-yloxyphenyl)-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CN=C1 LPYJHGOLVXMURG-UHFFFAOYSA-N 0.000 claims 1
- KBERIAMOVOHZDC-UHFFFAOYSA-N 6-methyl-4-(5-methylsulfonyl-2-quinolin-6-yloxyphenyl)-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound N1=CC=CC2=CC(OC3=CC=C(C=C3C3=CN(C(C=4NC=CC=43)=O)C)S(C)(=O)=O)=CC=C21 KBERIAMOVOHZDC-UHFFFAOYSA-N 0.000 claims 1
- SIYHXSWEEDVTNX-UHFFFAOYSA-N 6-methyl-4-(5-methylsulfonyl-2-quinolin-7-yloxyphenyl)-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=CC=NC2=CC(OC3=CC=C(C=C3C3=CN(C(C=4NC=CC=43)=O)C)S(C)(=O)=O)=CC=C21 SIYHXSWEEDVTNX-UHFFFAOYSA-N 0.000 claims 1
- PDEAWFQUQLIYSE-UHFFFAOYSA-N 6-methyl-4-(5-nitro-2-phenoxyphenyl)-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC([N+]([O-])=O)=CC=C1OC1=CC=CC=C1 PDEAWFQUQLIYSE-UHFFFAOYSA-N 0.000 claims 1
- YNCLQRAMKPEORE-UHFFFAOYSA-N 6-methyl-4-[2-(2-methylpropoxy)-5-methylsulfonylphenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound CC(C)COC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 YNCLQRAMKPEORE-UHFFFAOYSA-N 0.000 claims 1
- FVKQNASWVAWGQS-UHFFFAOYSA-N 6-methyl-4-[2-(2-methylpyridin-3-yl)oxy-5-methylsulfonylphenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound CC1=NC=CC=C1OC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 FVKQNASWVAWGQS-UHFFFAOYSA-N 0.000 claims 1
- CNZLKNXWPUJEAT-UHFFFAOYSA-N 6-methyl-4-[2-(4-methylcyclohexyl)oxy-5-methylsulfonylphenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1CC(C)CCC1OC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 CNZLKNXWPUJEAT-UHFFFAOYSA-N 0.000 claims 1
- VAJKJBSCCKXWGD-UHFFFAOYSA-N 6-methyl-4-[2-(4-methylphenoxy)-5-methylsulfonylphenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=CC(C)=CC=C1OC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 VAJKJBSCCKXWGD-UHFFFAOYSA-N 0.000 claims 1
- JIPVQCFNAUJNTN-UHFFFAOYSA-N 6-methyl-4-[2-(morpholin-4-ylmethyl)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC=CC=C1CN1CCOCC1 JIPVQCFNAUJNTN-UHFFFAOYSA-N 0.000 claims 1
- XAYJEYRRJGLAKV-UHFFFAOYSA-N 6-methyl-4-[2-(morpholine-4-carbonyl)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC=CC=C1C(=O)N1CCOCC1 XAYJEYRRJGLAKV-UHFFFAOYSA-N 0.000 claims 1
- DXBHWKBSHLNKCZ-UHFFFAOYSA-N 6-methyl-4-[2-[(1-methylcyclopropyl)methoxy]-5-methylsulfonylphenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OCC1(C)CC1 DXBHWKBSHLNKCZ-UHFFFAOYSA-N 0.000 claims 1
- BYLLNEGCIQBVEM-UHFFFAOYSA-N 6-methyl-4-[2-[(2-methylcyclopropyl)methoxy]-5-methylsulfonylphenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound CC1CC1COC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 BYLLNEGCIQBVEM-UHFFFAOYSA-N 0.000 claims 1
- SMPRDRCZDFCFRT-UHFFFAOYSA-N 6-methyl-4-[2-[1-[(2-methylpropan-2-yl)oxy]propan-2-yloxy]-5-methylsulfonylphenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound CC(C)(C)OCC(C)OC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 SMPRDRCZDFCFRT-UHFFFAOYSA-N 0.000 claims 1
- VVWUWZIRAUGLMS-UHFFFAOYSA-N 6-methyl-4-[2-[2-(1-methylpyrrolidin-2-yl)ethoxy]-5-methylsulfonylphenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound CN1CCCC1CCOC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 VVWUWZIRAUGLMS-UHFFFAOYSA-N 0.000 claims 1
- PLFYIWOUFTWZDE-AWEZNQCLSA-N 6-methyl-4-[2-[[(2s)-1-methylpyrrolidin-2-yl]methoxy]-5-methylsulfonylphenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound CN1CCC[C@H]1COC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 PLFYIWOUFTWZDE-AWEZNQCLSA-N 0.000 claims 1
- BHKWHTCFBHLJLR-UHFFFAOYSA-N 6-methyl-4-[2-phenoxy-5-(pyrazol-1-ylmethyl)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C(C(=CC=1)OC=2C=CC=CC=2)=CC=1CN1C=CC=N1 BHKWHTCFBHLJLR-UHFFFAOYSA-N 0.000 claims 1
- JDTJMPHCOISQET-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-(2-morpholin-4-ylethoxy)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OCCN1CCOCC1 JDTJMPHCOISQET-UHFFFAOYSA-N 0.000 claims 1
- FRFZFOWTBUHOKP-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-(3,4,5-trifluorophenoxy)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC(F)=C(F)C(F)=C1 FRFZFOWTBUHOKP-UHFFFAOYSA-N 0.000 claims 1
- YWWZBXQRIIQHTD-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-(4-methylsulfonylphenoxy)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=C(S(C)(=O)=O)C=C1 YWWZBXQRIIQHTD-UHFFFAOYSA-N 0.000 claims 1
- SOIJTMNMJXCALJ-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-(4-propan-2-ylphenoxy)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=CC(C(C)C)=CC=C1OC1=CC=C(S(C)(=O)=O)C=C1C1=CN(C)C(=O)C2=C1C=CN2 SOIJTMNMJXCALJ-UHFFFAOYSA-N 0.000 claims 1
- JENZEOHHTZWURR-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-(oxolan-3-ylamino)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1NC1CCOC1 JENZEOHHTZWURR-UHFFFAOYSA-N 0.000 claims 1
- NKOOGHIRLJDNDB-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-(oxolan-3-ylmethoxy)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OCC1CCOC1 NKOOGHIRLJDNDB-UHFFFAOYSA-N 0.000 claims 1
- PYMSOFJUXGJNNG-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-(oxolan-3-ylmethylamino)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1NCC1CCOC1 PYMSOFJUXGJNNG-UHFFFAOYSA-N 0.000 claims 1
- HOIDUDVLUDMEOH-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-(oxolan-3-yloxy)phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1CCOC1 HOIDUDVLUDMEOH-UHFFFAOYSA-N 0.000 claims 1
- JOOXTAGDTZFBTP-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-[2-(2-oxoimidazolidin-1-yl)ethoxy]phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OCCN1CCNC1=O JOOXTAGDTZFBTP-UHFFFAOYSA-N 0.000 claims 1
- IXNRLYXTIWKHPM-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-[2-(2-oxopyrrolidin-1-yl)ethoxy]phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OCCN1CCCC1=O IXNRLYXTIWKHPM-UHFFFAOYSA-N 0.000 claims 1
- AKKCQZBOXDRAEN-UHFFFAOYSA-N 6-methyl-4-[5-methylsulfonyl-2-[3-(trifluoromethyl)phenoxy]phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC1=CC=CC(C(F)(F)F)=C1 AKKCQZBOXDRAEN-UHFFFAOYSA-N 0.000 claims 1
- GWVXZKNCLCBSFJ-GFCCVEGCSA-N 6-methyl-4-[5-methylsulfonyl-2-[[(2r)-5-oxopyrrolidin-2-yl]methoxy]phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC[C@H]1CCC(=O)N1 GWVXZKNCLCBSFJ-GFCCVEGCSA-N 0.000 claims 1
- GWVXZKNCLCBSFJ-LBPRGKRZSA-N 6-methyl-4-[5-methylsulfonyl-2-[[(2s)-5-oxopyrrolidin-2-yl]methoxy]phenyl]-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(S(C)(=O)=O)=CC=C1OC[C@@H]1CCC(=O)N1 GWVXZKNCLCBSFJ-LBPRGKRZSA-N 0.000 claims 1
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- MCXAMGDOPCVCLB-IYBDPMFKSA-N C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1O[C@@H]1CC[C@H](OC)CC1 Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1O[C@@H]1CC[C@H](OC)CC1 MCXAMGDOPCVCLB-IYBDPMFKSA-N 0.000 claims 1
- NBRRDAGQJCKBBQ-SHTZXODSSA-N C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1O[C@H]1CC[C@H](O)CC1 Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1O[C@H]1CC[C@H](O)CC1 NBRRDAGQJCKBBQ-SHTZXODSSA-N 0.000 claims 1
- MCXAMGDOPCVCLB-WKILWMFISA-N C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1O[C@H]1CC[C@H](OC)CC1 Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(S(=O)(=O)CC)=CC=C1O[C@H]1CC[C@H](OC)CC1 MCXAMGDOPCVCLB-WKILWMFISA-N 0.000 claims 1
- HLPOGWGIWHXJTC-UHFFFAOYSA-N CCS(C(C=C1)=CC(N(C=C2)C3=C2C=CN(C)C3=O)=C1OC(CC1)CCS1(=O)=O)(=O)=O Chemical compound CCS(C(C=C1)=CC(N(C=C2)C3=C2C=CN(C)C3=O)=C1OC(CC1)CCS1(=O)=O)(=O)=O HLPOGWGIWHXJTC-UHFFFAOYSA-N 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010054949 Metaplasia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- IKIYHSFKHXHJBL-UHFFFAOYSA-N N-[3-(6-methyl-7-oxo-1H-pyrrolo[2,3-d]pyridazin-4-yl)-4-phenoxyphenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)N=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 IKIYHSFKHXHJBL-UHFFFAOYSA-N 0.000 claims 1
- WLFQFNBGLJCCIC-UHFFFAOYSA-N N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1H-pyrrolo[2,3-d]pyridazin-4-yl)phenyl]ethanesulfonamide Chemical compound N=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F WLFQFNBGLJCCIC-UHFFFAOYSA-N 0.000 claims 1
- WMZLURKVVFOFFQ-UHFFFAOYSA-N N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1H-pyrrolo[2,3-d]pyridazin-4-yl)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)N=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F WMZLURKVVFOFFQ-UHFFFAOYSA-N 0.000 claims 1
- CBYYDRRKLHBXOZ-UHFFFAOYSA-N N-ethyl-4-[5-(methanesulfonamido)-2-phenoxyphenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-d]pyridazine-2-carboxamide Chemical compound N=1N(C)C(=O)C=2NC(C(=O)NCC)=CC=2C=1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 CBYYDRRKLHBXOZ-UHFFFAOYSA-N 0.000 claims 1
- PJMZHQZVEZWPHJ-UHFFFAOYSA-N N-ethyl-4-[5-(methanesulfonamido)-2-phenoxyphenyl]-N,6-dimethyl-7-oxo-1H-pyrrolo[2,3-d]pyridazine-2-carboxamide Chemical compound N=1N(C)C(=O)C=2NC(C(=O)N(C)CC)=CC=2C=1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 PJMZHQZVEZWPHJ-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 102100023874 RING-box protein 2 Human genes 0.000 claims 1
- 101710178917 RING-box protein 2 Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010070863 Toxicity to various agents Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 208000019748 bullous skin disease Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 claims 1
- NDSAZMQUPJDUJC-UHFFFAOYSA-N ethyl 3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxybenzoate Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(C(=O)OCC)=CC=C1OC1=CC=CC=C1 NDSAZMQUPJDUJC-UHFFFAOYSA-N 0.000 claims 1
- LRBCEURUHXHASZ-UHFFFAOYSA-N ethyl 4-(5-amino-2-phenoxyphenyl)-6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridine-2-carboxylate Chemical compound C=1N(C)C(=O)C=2NC(C(=O)OCC)=CC=2C=1C1=CC(N)=CC=C1OC1=CC=CC=C1 LRBCEURUHXHASZ-UHFFFAOYSA-N 0.000 claims 1
- SOTOYEPXQBPCHF-UHFFFAOYSA-N ethyl 4-(cyclopentylamino)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)benzoate Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(C(=O)OCC)=CC=C1NC1CCCC1 SOTOYEPXQBPCHF-UHFFFAOYSA-N 0.000 claims 1
- TYIIDVJWGQZGCX-UHFFFAOYSA-N ethyl 4-[5-(ethylamino)-2-phenoxyphenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate Chemical compound N=1N(C)C(=O)C=2NC(C(=O)OCC)=CC=2C=1C1=CC(NCC)=CC=C1OC1=CC=CC=C1 TYIIDVJWGQZGCX-UHFFFAOYSA-N 0.000 claims 1
- WLJWEGGIMJRPNK-UHFFFAOYSA-N ethyl 4-[5-(methanesulfonamido)-2-phenoxyphenyl]-6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridine-2-carboxylate Chemical compound C=1N(C)C(=O)C=2NC(C(=O)OCC)=CC=2C=1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 WLJWEGGIMJRPNK-UHFFFAOYSA-N 0.000 claims 1
- WYAZPPJNVFARMZ-UHFFFAOYSA-N ethyl 4-[5-[ethyl(methylsulfonyl)amino]-2-phenoxyphenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate Chemical compound N=1N(C)C(=O)C=2NC(C(=O)OCC)=CC=2C=1C1=CC(N(CC)S(C)(=O)=O)=CC=C1OC1=CC=CC=C1 WYAZPPJNVFARMZ-UHFFFAOYSA-N 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000002409 gliosarcoma Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000015689 metaplastic ossification Effects 0.000 claims 1
- LRXNVAIQOGFUQW-UHFFFAOYSA-N methyl 6-methyl-7-oxo-4-(2-phenoxyphenyl)-1h-pyrrolo[2,3-c]pyridine-2-carboxylate Chemical compound C=1N(C)C(=O)C=2NC(C(=O)OC)=CC=2C=1C1=CC=CC=C1OC1=CC=CC=C1 LRXNVAIQOGFUQW-UHFFFAOYSA-N 0.000 claims 1
- 125000002912 morpholin-4-ylsulfonyl group Chemical group O1C([H])([H])C([H])([H])N(S(=O)(=O)[*])C([H])([H])C1([H])[H] 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000001167 myeloblast Anatomy 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- DKJPGEIOLHXOGH-UHFFFAOYSA-N n,n-dimethyl-2-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenylmethoxyphenyl]acetamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(CC(=O)N(C)C)=CC=C1OCC1=CC=CC=C1 DKJPGEIOLHXOGH-UHFFFAOYSA-N 0.000 claims 1
- GDCAGGAWVJAPOC-UHFFFAOYSA-N n-(1,1-dioxothiolan-3-yl)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxybenzamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(=O)NC2CS(=O)(=O)CC2)=CC=C1OC1=CC=CC=C1 GDCAGGAWVJAPOC-UHFFFAOYSA-N 0.000 claims 1
- PESGHFNOJXFWSQ-UHFFFAOYSA-N n-(2,2-difluoroethyl)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxybenzamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(=O)NCC(F)F)=CC=C1OC1=CC=CC=C1 PESGHFNOJXFWSQ-UHFFFAOYSA-N 0.000 claims 1
- UUHZVQLVXOCUNX-UHFFFAOYSA-N n-[2-cyano-4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound C1=C(C#N)C(NS(=O)(=O)CC)=CC(C=2C=3C=CNC=3C(=O)N(C)C=2)=C1OC1=CC=C(F)C=C1F UUHZVQLVXOCUNX-UHFFFAOYSA-N 0.000 claims 1
- OUTUXJWUAZLJOK-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(2,4,6-trifluorophenoxy)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=C(F)C=C(F)C=C1F OUTUXJWUAZLJOK-UHFFFAOYSA-N 0.000 claims 1
- CNZVJFFZAXTOLD-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(2,4,6-trifluorophenoxy)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=C(F)C=C(F)C=C1F CNZVJFFZAXTOLD-UHFFFAOYSA-N 0.000 claims 1
- SYHMIUKACGVZRQ-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(2,4,6-trifluorophenoxy)phenyl]propane-1-sulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CCC)=CC=C1OC1=C(F)C=C(F)C=C1F SYHMIUKACGVZRQ-UHFFFAOYSA-N 0.000 claims 1
- OWIKIYFYTBPQPO-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxan-3-yloxy)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1CCCOC1 OWIKIYFYTBPQPO-UHFFFAOYSA-N 0.000 claims 1
- ZRRBSTJCEDFLCE-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxan-3-yloxy)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1CCCOC1 ZRRBSTJCEDFLCE-UHFFFAOYSA-N 0.000 claims 1
- OITYKYVNANOBFD-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxan-3-yloxy)phenyl]propane-1-sulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CCC)=CC=C1OC1CCCOC1 OITYKYVNANOBFD-UHFFFAOYSA-N 0.000 claims 1
- JIJWTCHBAPFVMX-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxan-4-yloxy)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1CCOCC1 JIJWTCHBAPFVMX-UHFFFAOYSA-N 0.000 claims 1
- OECWOMUGQVHRAA-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxan-4-yloxy)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1CCOCC1 OECWOMUGQVHRAA-UHFFFAOYSA-N 0.000 claims 1
- BMHGLMHJVWJKHW-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxan-4-yloxy)phenyl]propane-1-sulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CCC)=CC=C1OC1CCOCC1 BMHGLMHJVWJKHW-UHFFFAOYSA-N 0.000 claims 1
- JRTGEOPRWAWWFO-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxolan-3-yloxy)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1CCOC1 JRTGEOPRWAWWFO-UHFFFAOYSA-N 0.000 claims 1
- RRGNRVIUYDBUFI-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-(oxolan-3-yloxy)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1CCOC1 RRGNRVIUYDBUFI-UHFFFAOYSA-N 0.000 claims 1
- LLNZXYDRSQLCBK-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-[2-(trifluoromethyl)phenoxy]phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1C(F)(F)F LLNZXYDRSQLCBK-UHFFFAOYSA-N 0.000 claims 1
- LSWNHXHXFDIKEX-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxyphenyl]acetamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NC(=O)C)=CC=C1OC1=CC=CC=C1 LSWNHXHXFDIKEX-UHFFFAOYSA-N 0.000 claims 1
- JEALBKSAOZOBET-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxyphenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 JEALBKSAOZOBET-UHFFFAOYSA-N 0.000 claims 1
- ZXUXOEACJYQVPI-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenylmethoxyphenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OCC1=CC=CC=C1 ZXUXOEACJYQVPI-UHFFFAOYSA-N 0.000 claims 1
- HEEOXLUVHGNZHB-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-pyridin-3-yloxyphenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CN=C1 HEEOXLUVHGNZHB-UHFFFAOYSA-N 0.000 claims 1
- XAARGHYZIMMIKR-UHFFFAOYSA-N n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-pyrimidin-5-yloxyphenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CN=CN=C1 XAARGHYZIMMIKR-UHFFFAOYSA-N 0.000 claims 1
- JMJNNESOGRQSCV-UHFFFAOYSA-N n-[3-[2-(hydroxymethyl)-6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl]-4-phenoxyphenyl]methanesulfonamide Chemical compound C1=2C=C(CO)NC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 JMJNNESOGRQSCV-UHFFFAOYSA-N 0.000 claims 1
- SKNPCCGYKZLRHL-UHFFFAOYSA-N n-[3-chloro-5-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxyphenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC(Cl)=C1OC1=CC=CC=C1 SKNPCCGYKZLRHL-UHFFFAOYSA-N 0.000 claims 1
- MAEDJUGOIKDPTL-UHFFFAOYSA-N n-[4-(2,2-dimethylpropoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC1=CC=C(OCC(C)(C)C)C(C=2C=3C=CNC=3C(=O)N(C)C=2)=C1 MAEDJUGOIKDPTL-UHFFFAOYSA-N 0.000 claims 1
- QLYQMTDQCDPCLA-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrazolo[3,4-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NN=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F QLYQMTDQCDPCLA-UHFFFAOYSA-N 0.000 claims 1
- SQANATOKRFCNRB-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-2,2-dimethylpropanamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NC(=O)C(C)(C)C)=CC=C1OC1=CC=C(F)C=C1F SQANATOKRFCNRB-UHFFFAOYSA-N 0.000 claims 1
- SHTZSDMHMQUVAA-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-2-fluoroethanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(=O)(=O)CCF)=CC=C1OC1=CC=C(F)C=C1F SHTZSDMHMQUVAA-UHFFFAOYSA-N 0.000 claims 1
- DSHHMKZISVPJGX-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-2-methoxyethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CCOC)=CC=C1OC1=CC=C(F)C=C1F DSHHMKZISVPJGX-UHFFFAOYSA-N 0.000 claims 1
- YEDQXGWUSMQOIE-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-3,3,3-trifluoropropanamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NC(=O)CC(F)(F)F)=CC=C1OC1=CC=C(F)C=C1F YEDQXGWUSMQOIE-UHFFFAOYSA-N 0.000 claims 1
- QAAXQVPFXYTKSZ-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-n-(2-methoxyethyl)ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(N(CCOC)S(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F QAAXQVPFXYTKSZ-UHFFFAOYSA-N 0.000 claims 1
- PEEMEKBCFWLWLB-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-n-(pyridin-2-ylmethyl)ethanesulfonamide Chemical compound C=1C=C(OC=2C(=CC(F)=CC=2)F)C(C=2C=3C=CNC=3C(=O)N(C)C=2)=CC=1N(S(=O)(=O)CC)CC1=CC=CC=N1 PEEMEKBCFWLWLB-UHFFFAOYSA-N 0.000 claims 1
- RDIRLLAOKZKJSN-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-n-[2-(dimethylamino)ethyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(N(CCN(C)C)S(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F RDIRLLAOKZKJSN-UHFFFAOYSA-N 0.000 claims 1
- RRTINPRKKRIIMO-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]acetamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NC(=O)C)=CC=C1OC1=CC=C(F)C=C1F RRTINPRKKRIIMO-UHFFFAOYSA-N 0.000 claims 1
- WZDGTJOAZLDFEB-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]cyclopropanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C(C(=CC=1)OC=2C(=CC(F)=CC=2)F)=CC=1NS(=O)(=O)C1CC1 WZDGTJOAZLDFEB-UHFFFAOYSA-N 0.000 claims 1
- RDONXGFGWSSFMY-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F RDONXGFGWSSFMY-UHFFFAOYSA-N 0.000 claims 1
- AKWTUXWXJYRCCZ-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1F AKWTUXWXJYRCCZ-UHFFFAOYSA-N 0.000 claims 1
- BNJQSKABORNTNE-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-[2-(hydroxymethyl)-6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl]phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC(CO)=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F BNJQSKABORNTNE-UHFFFAOYSA-N 0.000 claims 1
- VOJDRZCXELNEBL-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-[6-methyl-2-(4-methylpiperazine-1-carbonyl)-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl]phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC(C(=O)N3CCN(C)CC3)=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F VOJDRZCXELNEBL-UHFFFAOYSA-N 0.000 claims 1
- BPESJQPRQBZTGP-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-[6-methyl-3-(morpholin-4-ylmethyl)-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl]phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=C(CN3CCOCC3)C=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F BPESJQPRQBZTGP-UHFFFAOYSA-N 0.000 claims 1
- HFBQMUDGBKXMKA-UHFFFAOYSA-N n-[4-(2-chloro-4-fluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1Cl HFBQMUDGBKXMKA-UHFFFAOYSA-N 0.000 claims 1
- BZBXXZLEDBEPPB-UHFFFAOYSA-N n-[4-(2-cyanophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1C#N BZBXXZLEDBEPPB-UHFFFAOYSA-N 0.000 claims 1
- KYHHXNPMJKSACC-UHFFFAOYSA-N n-[4-(3,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=C(F)C(F)=C1 KYHHXNPMJKSACC-UHFFFAOYSA-N 0.000 claims 1
- AMUWMIJCYYNMDR-UHFFFAOYSA-N n-[4-(4,4-difluorocyclohexyl)oxy-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-2,2,2-trifluoroethanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(=O)(=O)CC(F)(F)F)=CC=C1OC1CCC(F)(F)CC1 AMUWMIJCYYNMDR-UHFFFAOYSA-N 0.000 claims 1
- DSZKXPBFLFPOBA-UHFFFAOYSA-N n-[4-(4,4-difluorocyclohexyl)oxy-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1CCC(F)(F)CC1 DSZKXPBFLFPOBA-UHFFFAOYSA-N 0.000 claims 1
- BQTAFTTUFGQMED-UHFFFAOYSA-N n-[4-(4,4-difluorocyclohexyl)oxy-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]propane-1-sulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CCC)=CC=C1OC1CCC(F)(F)CC1 BQTAFTTUFGQMED-UHFFFAOYSA-N 0.000 claims 1
- RMJAEWAFYPZTGB-UHFFFAOYSA-N n-[4-(4-cyanophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-2-fluoroethanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(=O)(=O)CCF)=CC=C1OC1=CC=C(C#N)C=C1 RMJAEWAFYPZTGB-UHFFFAOYSA-N 0.000 claims 1
- DUJGTCFLBGWZDY-UHFFFAOYSA-N n-[4-(4-cyanophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(C#N)C=C1 DUJGTCFLBGWZDY-UHFFFAOYSA-N 0.000 claims 1
- PSPYDRJKXPDLBS-UHFFFAOYSA-N n-[4-(4-fluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=C(F)C=C1 PSPYDRJKXPDLBS-UHFFFAOYSA-N 0.000 claims 1
- HOGODDOYXJSQAO-UHFFFAOYSA-N n-[4-(cyclopropylmethoxy)-2-methyl-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=C(C)C(NS(=O)(=O)CC)=CC=C1OCC1CC1 HOGODDOYXJSQAO-UHFFFAOYSA-N 0.000 claims 1
- SYINEFUUXFBFNJ-UHFFFAOYSA-N n-[4-(cyclopropylmethoxy)-2-methyl-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]methanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C=1C(C)=C(NS(C)(=O)=O)C=CC=1OCC1CC1 SYINEFUUXFBFNJ-UHFFFAOYSA-N 0.000 claims 1
- JUGKQGJJCQXMCG-UHFFFAOYSA-N n-[4-(cyclopropylmethoxy)-2-methyl-5-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]methanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C=1C=C(NS(C)(=O)=O)C(C)=CC=1OCC1CC1 JUGKQGJJCQXMCG-UHFFFAOYSA-N 0.000 claims 1
- MTTDJZSUZKVYTJ-UHFFFAOYSA-N n-[4-(cyclopropylmethoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OCC1CC1 MTTDJZSUZKVYTJ-UHFFFAOYSA-N 0.000 claims 1
- KFHLXFKVLGELKK-UHFFFAOYSA-N n-[4-[(2,5-dimethylpyrazol-3-yl)methoxy]-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OCC1=CC(C)=NN1C KFHLXFKVLGELKK-UHFFFAOYSA-N 0.000 claims 1
- ZKMZBCLSLVYACG-UHFFFAOYSA-N n-[4-cyclohexyloxy-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1CCCCC1 ZKMZBCLSLVYACG-UHFFFAOYSA-N 0.000 claims 1
- CAPHIHHWPCNOCF-UHFFFAOYSA-N n-[4-cyclopentyloxy-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CC=C1OC1CCCC1 CAPHIHHWPCNOCF-UHFFFAOYSA-N 0.000 claims 1
- KMOPCVRJYKUTKZ-UHFFFAOYSA-N n-[5-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-6-phenoxypyridin-3-yl]methanesulfonamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(NS(C)(=O)=O)=CN=C1OC1=CC=CC=C1 KMOPCVRJYKUTKZ-UHFFFAOYSA-N 0.000 claims 1
- AJYIIPKYMMAWRV-UHFFFAOYSA-N n-cyclopentyl-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxybenzamide Chemical compound C1=2C=CNC=2C(=O)N(C)C=C1C1=CC(C(=O)NC2CCCC2)=CC=C1OC1=CC=CC=C1 AJYIIPKYMMAWRV-UHFFFAOYSA-N 0.000 claims 1
- IBACWTSDHCXKLS-UHFFFAOYSA-N n-ethyl-2-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenylmethoxyphenyl]acetamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(CC(=O)NCC)=CC=C1OCC1=CC=CC=C1 IBACWTSDHCXKLS-UHFFFAOYSA-N 0.000 claims 1
- CIFLXEVIBRCRMF-UHFFFAOYSA-N n-ethyl-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxybenzamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(C(=O)NCC)=CC=C1OC1=CC=CC=C1 CIFLXEVIBRCRMF-UHFFFAOYSA-N 0.000 claims 1
- LILKYFFCIMECOJ-UHFFFAOYSA-N n-ethyl-4-[5-(methanesulfonamido)-2-phenoxyphenyl]-6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridine-2-carboxamide Chemical compound C=1N(C)C(=O)C=2NC(C(=O)NCC)=CC=2C=1C1=CC(NS(C)(=O)=O)=CC=C1OC1=CC=CC=C1 LILKYFFCIMECOJ-UHFFFAOYSA-N 0.000 claims 1
- BRGGWUGRIPBKFT-UHFFFAOYSA-N n-methyl-n-[3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxyphenyl]methanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(N(C)S(C)(=O)=O)=CC=C1OC1=CC=CC=C1 BRGGWUGRIPBKFT-UHFFFAOYSA-N 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 238000013146 percutaneous coronary intervention Methods 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 210000003635 pituitary gland Anatomy 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
Claims (63)
- Inhibitoiji bromodomene Patentni zahtevki1. Spojina s formulo (I) ali njena farmacevtsko sprejemljiva sol kjerRx predstavlja vodik ali C1-C3 alkil; Ry is C1-C3 alkil, -(C2-C3 alkilenil)-OH ali C1-C3 haloalkil; X1 je N ali CRxl,kjer RxI je vodik, C2-C6 alkenil, C2-C6 alkinil, -C(0)0Raxl, -C(0)NRbxlRcxl, -C(0)Rdxl, S(0)2Rdxl, -S(0)2NRbxlRcxl, Gxl, Ci-C6 haloalkil ali C,-C6 alkil;, kjer je C1-C6 alkil neobvezno substituiran z enim substituentom izbranim iz skupine, ki vsebuje OR®1, SR3*1, S(0)Rdxl, SCO)^1, NRbxlRcxl, -CiOjR^1, -CCOjOR^1, -C(0)NRbxlRcxl, -S(0)2NRbxlRcxl in Gxl; vsak izmed R3*1, Rbxl in Rcxl je vsakokrat neodvisno vodik, C1-C6 alkil, C1-C6 haloalkil, Ga ali -(Ci-C6 alkilenil)-Ga; R^1 je vsakokrat neodvisno C1-C6 alkil, C1-C6 haloalkil, Ga ali -(C1-C6 alkilenil)-Ga; X2 je N ali CRx2;, kjer R^ predstavlja vodik, C2-C6 alkenil, C2-C6 alkinil, -CiOjOR3*2, -C(0)NRbx2Rcx2, -C(0)Rdx2, -C(0)H, S(0)2Rdx2, -S(0)2NRbx2Rcx2, G*2, Ci-C6 haloalkil ali C,-C6 alkil;, kjer je Ci-Cč alkil neobvezno substituiran z enim substituentom izbranim iz skupine, ki vsebuje OR8*2, SR8*2, S(0)Rdx2, StO^R**2, NR^R0*2, -CCOjR8*2, -CCOjOR3*2, -C(0)NRbx2Rcx2, -S(0)2NRbx2Rcx2 in G*2; vsak izmed R8*2, Rbx2 in Rcx2, je vsakokrat neodvisno vodik, Ci-C6 alkil, C1-C6 haloalkil, Gb ali -(C1-C6 alkilenil)-Gb; Rdx2 je vsakokrat neodvisno C1-C6 alkil, C1-C6 haloalkil, Gb ali -(C1-C6 alkilenil)-Gb; Υ1 je N ali CRU;, kjer je Ru vodik, C1-C6 alkil, halogen ali C1-C6 haloalkil; A1 je N ali CR1, A2 je N ali CR2, A3 je N ali CR3 in A4 je N ali CR4; pod pogojem, da nič, eden, dva ali trije izmed A1, A2, A3 in A4 predstavljajo N; vsak izmed R1, R3 in R4 je neodvisno vodik, C1-C6 alkil, C2-C6 alkenil, C2-Q alkinil, halogen, C1-C6 haloalkil, CN ali NO2; R2 je vodik, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, halogen, C1-C6 haloalkil, -CN, N02, G28, -OR28, -0C(0)R2d, -0C(0)NR2bR2c, -SR2a, -S(0)2R2d, -S(0)2NR2bR2c, -C(0)R2d, -C(0)0R2a, -C(0)NR2bR2c, -NR2bR2c, -N(R2e)C(0)R2d, -N(R2e)S(0)2R2d, -N(R2e)C(0)0(R2d), -N(R2e)C(0)N2bR2c, -N(R2e)S(0)2NR2bR2c, -(Ci-C6 alkilenil)-G2a, -(Ci-C6 alkilenil)-OR2a, -(Ci-C6 alkilenil)-0C(O)R2d, -(Ci-C6 alkilenil)-0C(0)NR2bR2c, -(Ci-C6 alkilenil)-S(0)2R2d, -(Ci-C6 alkilenil)-S(0)2NR2bR2c, -(Ci-C6 alkilenil)-C(0)R2d, -(Cj-Ce alkilenil)-C(0)OR2a, -(Cj-Ce alkilenil)-C(0)NR2bR2e, -(Ci-C6 alkilenil)-NR2bR2c, -(Ci-C6 alkilenil)-N(R2e)C(0)R2d, -(Ci-C6 alkilenil)-N(R2e)S(0)2R2d, -(C,-C6 alkilenil)-N(R2e)C(0)0(R2a), -(Ci-C6 alkilenil)-N(R2e)C(0)NR2bR2c, -(CrC6 alkilenil)-N(R2e)S(0)2NR2bR2c in-(CrC6 alkilenil)-CN; vsak izmed R2a, R2b, R2c in R2e, je vsakokrat neodvisno vodik, C2-C6 alkenil, C2-C6 alkinil, C1-C6 haloalkil, G2b ali C1-C6 alkil, kjer je Ci-Cg alkil neobvezno substituiran z enim substituentom izbranim iz skupine, ki vsebuje -ORzl, NrzIr22, _C(0)ORz1, -C(0)NRz1Rz2, -S(0)2Rz1, -S(0)2NRz1Rz2 in G2b; R2d je vsakokrat neodvisno C2-C6 alkenil, C2-C6 alkinil, Ci-C6 haloalkil, G2b ali C1-C6 alkil, kjer je Ci-Ce alkil neobvezno substituiran z enim substituentom izbranim iz skupine, ki vsebuje -ORzl, NR^R22, -C(0)0Rzl, -ClOjNR^R22, -S(0)2Rz1, -SCOjzNR2^22 in G2b; vsak izmed Rzl in R22, je vsakokrat neodvisno vodik, C1-C6 alkil ali Ci-Ce haloalkil; vsak izmed Gxl, G*2, Ga, Gb, G2a in G2b, je vsakokrat neodvisno aril, heteroaril, heterocikel, cikloalkil ali cikloalkenil, izmed katerih je vsak neodvisno nesubstituiran ali substituiran z 1, 2, 3, 4 ali 5 Rv; L1 je odsoten, CH2, C(O), C(H)(OH), (CH2)mO, (CH2)mS(0)„, kjer je n enako 0, 1 ali 2; ali (CH2)mN(Rz), kjer je Rz vodik, C1-C3 alkil, C1-C3 haloalkil, (C2-C3 alkilenil)-OH ali nesubstituiran ciklopropil; m je 0 ali 1; G1 je Ci-Ce alkil, alkoksialkil, Gla ali -(C1-C6 alkilenil)-Gla;, kjer je vsak Gla neodvisno aril, heteroaril, heterocikel, cikloalkil ali cikloalkenil in vsak Gla je neodvisno nesubstituiran ali substituiran z 1,2, 3,4 ali 5 Rw; vsak izmed Rv in Rw, je vsakokrat neodvisno C1-C6 alkil, C2-Ce alkenil, C2-C6 alkinil, halogen, C1-C6 haloalkil, -CN, okso, -ORh, -0C(0)R', -0C(0)NRjRk, -SRh, -S(0)2Rh, -S(0)2NRjRk, -C(0)Rh, -C(0)-monocikličen heterocikel, -C(O)-monocikličen heteroaril,-C(0)0Rh, -C(0)NRjRk, -NRjRk, -NCR^ClOjR, -N(Rh)S(0)2R\ -1^)0(0)0(^), -N(Rh)C(0)NRjRk, -(Ci-C6 alkilenil)-ORh, -(Ci-C6 alkilenil)-OC(0)R', -(Ci-C6 alkilenil)-OC(0)NRjRk, -(Ci-C6 alkilenil)-S(0)2Rh, -(Ci-C6 alkilenil)-S(0)2NRjRk, -(Ci-C6 alkilenil)-C(0)Rh, -(Ci-C6 alkilenil)-C(0)ORh, -(Ci-C6 alkilenil)-C(0)NRjRk, -(Ci-C6 alkilenil)-NRjRk, -(Ci-C6 alkilenil)-N(Rh)C(0)R‘, -(CrC6 alkilenil)-N(Rh)S(0)2Ri, -(Ci-C6 alkilenil)-N(Rh)C(0)0(R'), -(Ci-C6 alkilenil)-N(Rh)C(0)NRjRk ali -(CrC6 alkilenil)-CN; vsak izmed Rh, RJ, Rk, je vsakokrat neodvisno vodik, C1-C6 alkil ali C1-C6 haloalkil; in R1 je vsakokrat neodvisno C1-C6 alkil ali C1-C6 haloalkil.
- 2. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer R5'2 predstavlja vodik, C2-C6 alkenil, C2-C6 alkinil, -CtOjOR3*2, -C(0)NRbx2Rcx2, -C(0)Rdx2, S(0)2Rdx2, -S(0)2NRbx2Rcx2, G*2, Ci-C6 haloalkil ali Ci-C6 alkil;, kjer je C1-C6 alkil neobvezno substituiran z enim substituentom izbranim iz skupine, ki vsebuje OR3*2, SR3*2, S(0)Rdx2, S(0)2Rdx2, NRbx2Rcx2, -C^R3*2, -CCOjOR3*2, -C(0)NRbx2Rcx2, -S(0)NRbx2Rcx2 in G*2; L1 je odsoten, CH2, C(O), (CH2)mO, (CH2)mS(0)n, kjer je n enako 0,1 ali 2; ali (CH2)mN(Rz), kjer je Rz vodik, C1-C3 alkil, C1-C3 haloalkil, (C2-C3 alkilenil)-OH ali nesubstituiran ciklopropil; G1 is Gla ali -(C1-C6 alkilenil)-Gla;, kjer je vsak Gla neodvisno aril, heteroaril, heterocikel, cikloalkil ali cikloalkenil in vsak Gla je neodvisno nesubstituiran ali substituiran z 1,2,3,4 ali 5 Rw; in vsak izmed Rv in Rw, je vsakokrat neodvisno C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, halogen, Ci-C6 haloalkil, -CN, okso, -ORh, -0C(0)R\ -0C(0)NRjRk, -SRh, -S(0)2Rh, -S(0)2NRjRk, -C(0)Rh, -C(0)0Rh, -C(0)NRjRk, -NRjRk, -N(Rh)C(0)R‘, -N(Rh)S(0)2Ri, -N(Rh)C(0)0(R’>, -N(Rh)C(0)NRjRk, -(Ci-C6 alkilenil)-ORh, -(Ci-C6 alkilenilj-OCCOjR, -(Ci-C6 alkilenil)-0C(0)NRjRk, -(Ci-C6 alkilenil)-S(0)2Rh, -(Ci-C6 alkilenil)-S(0)2NRjRk, -(Ci-C6 alkilenil)-C(0)Rh, -(CrC6 alkilenil)-C(0)0Rh, -(Ci-C6 alkilenil)-C(0)NRjRk, -(CrC6 alkilenil)-NRjRk, -(Ci-C6 alkilenil)-N(Rh)C(0)R', -(Ci-C6 alkilenil)-N(Rh)S(0)2R', -(C!-C6 alkilenil)-N(Rh)C(0)0(R'), -(Ci-C6 alkilenil)-N(Rh)C(0)NRjRk ali -(Ci-C6 alkilenil)-CN.
- 3. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer Ry predstavlja C1-C3 alkil.
- 4. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer Ry predstavlja metil.
- 5. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer X1 predstavlja CRxl; in X2 je CR*2.
- 6. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer Υ1 predstavlja N.
- 7. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer Υ1 predstavlja CR“.
- 8. Spojina po zahtevku 6 ali njena farmacevtsko sprejemljiva sol, kjer Ru predstavlja vodik ali C1-C3 alkil.
- 9. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer L1 predstavlja CH2, C(O), (CH2)mO ali (CH2)mN(Rz).
- 10. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer L1 predstavlja (CH2)mO in G1 is Gla.
- 11. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer A1 predstavlja CR1; A2 je CR2; A3 je CR3; in A4 je CR4.
- 12. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer eden izmed A1, A2, A3 in A4 predstavlja N.
- 13. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer je R2 vodik, Ci-C6 alkil, N02, G2a, -S(0)2R2d, -S(0)2NR2bR2c, -C(0)R2d, -C(0)0R2a, -C(0)NR2bR2c, -NR2bR2c, -N(R2e)C(0)R2d, -N(R2e)S(0)2R2d, -N(R2e)S(0)2NR26R2c, -(Ci-C6 alkilenil)-G2a, -(Ci-C6 alkilenil)-OR2a, -(Ci-C6 alkilenil)-S(0)2R2d, -(Ci-C6 alkilenil)-S(0)2NR2bR2c, -(CrC6 alkilenil)-C(0)R2d, (CrC6 alkilenil)-C(0)OR2a, -(Ci-C6 alkilenil)-C(0)NR2bR2c, -(Ci-C6 alkilenil)-NR2bR2c, -(Ci-C6 alkilenil)-N(R2e)C(0)R2d, -(C,-C6 alkilenil)-N(R2e)S(0)2R2d ali -(Ci-C6alkilenil)-N(R2e)S(0)2NR2bR2c.
- 14. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer je R2 -S(0)2R2d, -S(0)2NR2bR2e, -C(0)R2d, -C(0)NR2bR2c, -N(R2e)C(0)R2d, -N(R2e)S(0)2R2d, -N(R2e)S(0)2NR2bR2c, -(Ci-C6 alkilenil)-S(0)2R2d, -(Ci-C6 alkilenil)-S(0)2NR2bR2c, -(Ci-C6 alkilenil)-C(0)R2d, -(Ci-C6 alkilenil)-C(0)NR2bR2c, -(Ci-C6 alkilenil)-N(R2e)C(0)R2d, -(C,-C6 alkilenil)-N(R2e)S(0)2R2d ali -(Ci-C6 alkilenil)-N(R2e)S(0)2NR2bR2c.
- 15. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer je R2 -S(0)2R2d, -S(0)2NR2bR2c, -N(R2e)S(0)2R2d ali -N(R2e)S(0)2NR2bR2c.
- 16. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer Υ1 predstavlja N; X1 je CRxl; in X2 je CR*2.
- 17. Spojina po zahtevku 16 ali njena farmacevtsko sprejemljiva sol, kjerje spojina izbrana iz skupine, ki vsebuje: etil 4-(5-amino-2-fenoksifenil)-6-metil-7-okso-6,7-dihidro-1 H-pirolo[2,3- d]piridazin-2-karboksilat; etil 4-[5-(etilamino)-2-fenoksifenil]-6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- d]piridazin-2-karboksilat; etil 4- {5 - [etil(metilsulfonil)amino] -2-fenoksifenil} -6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-d]piridazin-2-karboksilat; 6-metil-4- {5-[(metilsulfonil)amino]-2-fenoksifenil}-7-okso-6,7-dihidro-1H-pirolo[2,3-d]piridazin-2-karboksilna kislina; 6-metil-4- {5 - [(metilsulfonil)amino]-2-fenoksifenil} -7-okso-6,7 -dihidro-1H-pirolo[2,3 -d]piridazin-2-karboksamid; 6-metil-N-[2-(4-metilpiperazin-l-il)etil]-4-{5-[(metilsulfonil)amino]-2- fenoksifenil}-7-okso-6,7-dihidro-lH-pirolo[2,3-d]piridazin-2-karboksamid; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-d]piridazin-4-il)-4- fenoksifeniljmetansulfonamid; N-etil-6-metil-4-{5-[(metilsulfonil)amino]-2-fenoksifenil}-7-okso-6,7-dihidro- lH-pirolo[2,3-d]piridazin-2-karboksamid; 6-metil-4-(2-fenoksifenil)-l,6-dihidro-7H-pirolo[2,3-d]piridazin-7-on; N-etil-N,6-dimetil-4-{5-[(metilsulfonil)amino]-2-fenoksifenil}-7-okso-6,7-dihidro-1 H-pirolo[2,3-d]piridazin-2-karboksamid; 4-[5-amino-2-(2,4-difluorofenoksi)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- d]piridazin-7-on; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- d]piridazin-4-il)fenil]metansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-d]piridazin-4-il)fenil]etansulfonamid; in 4-[2-(ciklopropilmetoksi)-5-(etilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-d]piridazin-7-on.
- 18. Spojina po zahtevku 16 ali njena farmacevtsko sprejemljiva sol, kjer Ry predstavlja metil.
- 19. Spojina po zahtevku 18 ali njena farmacevtsko sprejemljiva sol, kjer L1 predstavlja CH2, C(O), (CH2)mO ali (CH2)mN(Rz).
- 20. Spojina po zahtevku 18 ali njena farmacevtsko sprejemljiva sol, kjer L1 predstavlja (CH2)mO.
- 21. Spojina po zahtevku 20 ali njena farmacevtsko sprejemljiva sol, kjer G1 predstavlja Gla.
- 22. Spojina po zahtevku 21 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja aril neodvisno nesubstituiran ali substituiran z 1, 2, 3, 4 ali 5 Rw.
- 23. Spojina po zahtevku 21 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja fenil neodvisno nesubstituiran ali substituiran z 1,2, 3, 4 ali 5 Rw.
- 24. Spojina po zahtevku 21 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja cikloalkil neodvisno nesubstituiran ali substituiran z 1,2, 3, 4 ali 5 Rw.
- 25. Spojina po zahtevku 21 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja monocikličen cikloalkil neodvisno nesubstituiran ali substituiran z 1, 2, 3,4 ali 5 Rw.
- 26. Spojina po zahtevku 21 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja heterocikel neodvisno nesubstituiran ali substituiran z 1, 2, 3,4 ali 5 Rw.
- 27. Spojina po zahtevku 21 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja monocikličen heterocikel neodvisno nesubstituiran ali substituiran z 1, 2, 3, 4 ali 5 Rw.
- 28. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer Υ1 predstavlja CRU; X1 je CRxl; in X2 je CR*2.
- 29. Spojina po zahtevku 28 ali njena farmacevtsko sprejemljiva sol, kjer je spojina izbrana iz skupine, ki vsebuje 6-metil-4-(2-fenoksifenil)-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 6-metil-4-(5-nitro-2-fenoksifenil)-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-(5-amino-2-fenoksifenil)-6-metil-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; N- [3 -(6-metil-7-okso-6,7-dihidro-1 H-pirolo [2,3 -c]piridin-4-il)-4-fenoksifeniljmetansulfonamid; 2,2,2-trifluoro-N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4- fenoksifeniljetansulfonamid; N- [3 -(6-metil-7-okso-6,7-dihidro-1 H-pirolo [2,3 -c]piridin-4-il)-4-fenoksifeniljacetamid; N-metil-N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4- fenoksifeniljmetansulfonamid; etil 3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-fenoksibenzoat; 3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-fenoksibenzojeva kislina; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(piridin-3- iloksi)fenil]metansulfonamid; 6-metil-4-[2-(morfolin-4-ilmetil)fenil]-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; N-etil-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4- fenoksibenzamid; 3 -(6-metil-7-okso-6,7-dihidro-1 H-pirolo [2,3 -c]piridin-4-il)-4-fenoksi-N-(tetrahidrofuran-2-ilmetil)benzamid; N-ciklopentil-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4- fenoksibenzamid; N-(2,2-difluoroetil)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)- 4-fenoksibenzamid; 3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-fenoksi-N-(l,3- tiazol-2-il)benzamid; N-(l,l-dioksidotetrahidrotiofen-3-il)-3-(6-metil-7-okso-6,7-dihidro-lH- pirolo[2,3-c]piridin-4-il)-4-fenoksibenzamid; 3- (6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-fenoksibenzamid; 4- [5 -(hidroksimetil)-2-fenoksifenil] -6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4- fenoksifeniljetansulfonamid; N,N-dimetil-N'-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]pmdin-4-il)-4-fenoksifenil] žveplov diamid; N-[5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-6-fenoksipiridin-3 -il]metansulfonamid; N-[3-fluoro-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4- fenoksifeniljmetansulfonamid; N-[4-(2-cianofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)fenil]metansulfonamid; N-[4-(4-fluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)fenil]metansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]metansulfonamid; N-[3-kloro-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4- fenoksifenil]metansulfonamid; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidro-2H- piran-4-iloksi)fenil]metansulfonaxnid; 6-metil-4-[2-fenoksi-5-(lH-pirazol-l-ilmetil)fenil]-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4- (tetrahidrofuran-3-iloksi)fenil]metansulfonamid; N- {3-(6-metil-7-okso-6,7-dihidro-1 H-pirolo[2,3-c]piridin-4-il)-4-[2-(trifluorometil)fenoksi] fenil} metansulfonamid; N-[4-(4-cianofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)fenil]metansulfonamid; N-[4-(2-kloro-4-fluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]metansulfonamid; [4-(benziloksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)fenil]ocetna kislina; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]etansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]acetamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-3,3,3-trifluoropropanamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-2,2-dimetilpropanamid; etil 4-(ciklopentilamino)-3 -(6-metil-7-okso-6,7-dihidro-1 H-pirolo[2,3 -c]piridin- 4-il)benzoat; 4-{5-[(l,l -dioksido-1,2-tiazolidin-2-il)metil] -2-fenoksifenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-{[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-fenoksibenzil]amino} -4-oksobutanoj ska kislina; 4- [2-(2,4-difluorofenoksi)-5-( 1,1 -dioksido-1,2-tiazolidin-2-il)fenil] -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(benziloksi)-5-(2-hidroksietil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; metil [4-(benziloksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)fenil] acetat; 2- [4-(benziloksi)-3 -(6-metil-7-okso-6,7-dihidro-1 H-pirolo [2,3-c]piridin-4-il)fenil]-N-etilacetamid; 2-[4-(benziloksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)fenil]-N,N-dimetilacetamid; N-[4-(3,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]metansulfonamid; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(2,4,6- trifluorofenoksi)fenil]metansulfonamid; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)benzamid; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)-N-(tetrahidrofuran-3-il)benzamid; 4-{2-(2,4-difluorofenoksi)-5-[(l,l-dioksidotiomorfolin-4-il)karbonil]fenil}-6- metil-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-N-( 1 -metil-2-oksopirolidin-3 -il)benzamid; tert-butil {1 -[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3 -c]piridin-4-il)benzoil]pirolidin-3 -il} karbamat; 4-[2-(2,4-difluorofenoksi)-5-(pirolidin-1 -ilkarbonil)fenil]-6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(morfolin-4-ilkarbonil)fenil]-6-metil-l,6-dihidro- 7H-pirolo[2,3-c]piridin-7-on; N-[4-(cikloheksiloksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)fenil]metansulfonamid; N-[4-(ciklopentiloksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)fenil]metansulfonamid; N- {4-[(4,4-difluorocikloheksil)oksi]-3-(6-metil-7-okso-6,7-dihidro-1H-pirolo [2,3-c]piridin-4-il)fenil} metansulfonamid; N- [3 -(6-metil-7-okso-6,7-dihidro-1 H-pirolo [2,3-c]piridin-4-il)-4-(tetrahidro-2H-piran-3-iloksi)fenil]metansulfonamid; 6-metil-4-[2-(morfolin-4-ilkarbonil)fenil]-l,6-dihidro-7H-pirolo[2,3-c]piridin-7- on; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(2,4,6- trifluorofenoksi)fenil]etansulfonamid; N-[4-(benziloksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)fenil]metansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-2-fluoroetansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)fenil]-N'-metil žveplov diamid; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidrofuran-3-iloksi)fenil]etansulfonamid; metil 6-metil-7-okso-4-(2-fenoksifenil)-6,7-dihidro-1 H-pirolo[2,3-c]piridin-2-karboksilat; metil l,6-dimetil-7-okso-4-(2-fenoksifenil)-6,7-dihidro-lH-pirolo[2,3-c]piridin-2-karboksilat; etil 4-(5-amino-2-fenoksifenil)-6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-2-karboksilat; 6-metil-4-(5-(metilsulfonamido)-2-fenoksifenil)-7-okso-6,7-dihidro-lH-pirolo [2,3 -c]piridin-2-karboksilna kislina; etil 6-metil-4- {5 - [(metilsulfonil)amino] -2-fenoksifenil} -7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-2-karboksilat; N-etil-6-metil-4- {5- [(metilsulfonil)amino] -2-fenoksifenil} -7-okso-6,7-dihidro-1 H-pirolo [2,3 -c]piridin-2-karboksamid; 6-metil-4- { 5 - [(metilsulfonil)amino] -2-fenoksifenil} -7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-2-karboksamid; 4-{4-[(etilsulfonil)amino]-2-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)fenoksi} benzamid; 6- metil-4-[5-(metilsulfonil)-2-fenoksifenil]-l,6-dihidro-7H-pirolo[2,3-c]piridin- 7- on; 5 -(6-metil-7-okso-6,7-dihidro-1 H-pirolo [2,3 -c]piridin-4-il)-6-(tetrahidrofuran-3 -iloksi)piridin-3-sulfonamid; N-metil-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-6-(tetrahidrofuran-3 -iloksi)piridin-3 -sulfonamid; 6-metil-4-(2-fenoksifenil)-2-fenil-1,6-dihidro-7H-pirolo[2,3 -c]piridin-7-on; N-{3-[2-(hidroksimetil)-6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il] -4-fenoksifenil} metansulfonamid; N-[4-(4-cianofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)fenil]etansulfonamid; 2- fluoro-N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidrofuran-3-iloksi)fenil]etansulfonamid; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidrofuran-3-iloksi)fenil]propan-1 -sulfonamid; N- [4-(4-cianofenoksi)-3 -(6-metil-7 -okso-6,7-dihidro-1 H-pirolo[2,3 -c]piridin-4-il)fenil]propan-1 -sulfonamid; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(2,4,6-trifluorofenoksi)fenil]propan-1 -sulfonamid; 3- (6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-fenoksibenzenesulfonamid; 6-(cikloheksilamino)-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)piridin-3 -sulfonamid; 6-(cikloheksilamino)-N-metil-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)piridin-3-sulfonamid; N-metil-N'-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(2,4,6-trifluorofenoksi)fenil]žveplov diamid; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidro-2H-piran-4-iloksi)fenil]propan-1 -sulfonamid; 2,2,2-trifluoro-N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidro-2H-piran-4-iloksi)fenil]etansulfonamid; N-{4-[(4,4-difluorocikloheksil)oksi]-3-(6-metil)-7-okso-6,7-dihidro-lH-piro! o[2,3 -c]piridin-4-il)fenil} etansulfonamid; N-{4-[(4,4-difluorocikloheksil)oksi]-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)fenil}propan-l-sulfonamid; N-{4-[(4,4-difluorocikloheksil)oksi]-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3 -c]piridin-4-il)fenil} -2,2,2-trifluoroetansulfonamid; N- {4-[(4,4-difluorocikloheksil)oksi]-3-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)fenil} -N'-metilžveplov diamid; N-[3-(6-metil-7-okso-6,7-diWdro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidro-2H-piran-3 -iloksi)fenil] etansulfonamid; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidro-2H-piran-3 -iloksi)fenil]propan-1 -sulfonamid; 2,2,2-trifluoro-N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidro-2H-piran-3-iloksi)fenil]etansulfonamid; N-metil-N'-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidro-2H-piran-3-iloksi)fenil]žveplov diamid; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(tetrahidro-2H- piran-4-iloksi)fenil]etansulfonamid; N,N-dimetil-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-6-(tetrahidrofuran-3 -iloksi)piridin-3 -sulfonamid; 5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-6-(fenilamino)piridin-3 -sulfonamid; N-metil-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-6-(fenilamino)piridin-3 -sulfonamid; N-[4-(4-cianofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)fenil]-2-fluoroetansulfonamid; 2-fluoro-N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(2,4,6-trifluorofenoksi)fenil]etansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)fenil]propan-1 -sulfonamid; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)-N-(pirimidin-2-il)benzamid; 4-(2,4-difluorofenoksi)-N-(2,6-dimetoksipiridin-3-il)-3-(6-metil-7-okso-6,7-dihidro-1 H-pirolo[2,3 -c]piridin-4-il)benzamid; 4-(2,4-difluorofenoksi)-N-( 1 H-indazol-6-il)-3-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)benzamid; 4-[2-(2,4-difluorofenoksi)-5-{ [4-(pirolidin-1 -ilkarbonil)piperazin-1 -iljkarbonil} fenil] -6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-(2,4-difluorofenoksi)-N-[4-(dimetilamino)fenil]-3-(6-metil-7-okso-6,7-dihidro-1 H-pirolo [2,3-c]piridin-4-il)benzamid; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)-N-(piridin-4-ilmetil)benzamid; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-N-[2-(2-oksopirolidin-1 -il)etil]benzamid; 4-(2,4-difluorofenoksi)-N-(2-hidroksi-2-metilpropil)-3-(6-metil-7-okso-6,7-dihidro-1 H-pirolo[2,3-c]piridin-4-il)benzamid; 4-(2,4-difluorofenoksi)-N-[2-(5-metoksi-lH-indol-3-il)etil]-3-(6-metil-7-okso- 6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)benzamid; N-(3,4-difluorobenzil)-4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-1 H-pirolo[2,3 -c]piridin-4-il)benzamid; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)-N-[4-(trifluorometoksi)benzil]benzamid; 2-{4-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)benzoil]piperazin-1 -il} -N,N-dimetilacetamid; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-N-(piridin-3-ilmetil)benzamid; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)-N-(piridin-2-ilmetil)benzamid; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)-N-(3,4,5-trimetoksibenzil)benzamid; 4-(2,4-difluorofenoksi)-N-[2-(dimetilamino)etil]-3-(6-metil-7-okso-6,7-dihidro-1 H-pirolo[2,3 -c]piridin-4-il)benzamid; N-[2-(l,3-benzodioksol-5-il)etil]-4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-1 H-pirolo[2,3-c]piridin-4-il)benzamid; 4-(2,4-difluorofenoksi)-N-[2-(lH-indol-3-il)etil]-3-(6-metil-7-okso-6,7-dihidro- lH-pirolo[2,3-c]piridin-4-il)benzamid; 4- [2-(2,4-difluorofenoksi)-5 - {[4-(furan-2-ilkarbonil)piperazin-1 -il]karbonil} fenil] -6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; tert-butil {l-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)benzoil]piperidin-4-il}karbamat; tert-butil 4-{[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)benzoil]amino}piperidine-l-karboksilat; 4-[2-(2,4-difluorofenoksi)-5-{[4-(etilsulfonil)piperazin-l-il]karbonil}fenil]-6-metil-1,6-dihidro-7H-pirolo [2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(4-klorobenzoil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-{2-[(4-klorofenil)(hidroksi)metil]fenil}-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; N-[3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(pirimidin-5- iloksi)fenil]etansulfonamid; N- {3 -(6-metil-7-okso-6,7-dihidro-1 H-pirolo [2,3 -c]piridin-4-il)-4- [(1 -metil-1H-pirazol-5 -il)metoksi] fenil} etansulfonamid; N- {4- [(1,3 -dimetil-1 H-pirazol- 5 -il)metoksi] -3 -(6-metil-7-okso-6,7-dihidro-1H-pirolo [2,3 -c]piridin-4-il)fenil} etansulfonamid; N-[4-(2,2-dimetilpropoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)fenil]etansulfonamid; N-[4-(ciklopropilmetoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]etansulfonamid; 4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)benzenesulfonamid; 4-[2-(cikloheksilamino)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4- [2-(2-fluorofenoksi)-5 -(metilsulfonil)fenil] -6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-[2-(3-fluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4-[2-(4-fluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4-[2-(2-klorofenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4- [2-(3 -klorofenoksi)-5-(metilsulfonil)fenil] -6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-[2-(4-klorofenoksi)-5-(metilsulfbnil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 3- [2-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(metilsulfonil)fenoksi]benzonitril; 4- [2-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(metilsulfonil)fenoksi]benzonitril; 6-metil-4- {5-(metilsulfonil)-2-[3-(trifluorometil)fenoksi]fenil} -1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(ciklopropilmetoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(izokinolin-5-iloksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo [2,3 -c] piridin-7-on; 6-metil-4-[5-(metiIsulfonil)-2-(kinolin-6-iloksi)fenil]-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4-{2-[2-kloro-5-(trifluorometil)fenoksi]-5-(metilsulfonil)fenil}-6-metil-l,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4- {2-[2-fluoro-5-(trifluorometil)fenoksi]-5-(metilsulfonil)fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 2-{4-[2-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(metilsulfonil)fenoksi] fenil} acetamid; 4- [2-(3 -aminofenoksi)-5 -(metilsulfonil)fenil] -6-metil-1,6-dihidro-7H-pirolo [2,3-c]piridin-7-on; 6-metil-4- [5 -(metilsulfonil)-2-(tetrahidrofuran-3 -ilamino)fenil] -1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(etilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4- {2- [(4,4-difluorocikloheksil)oksi] -5 -(etilsulfonil)fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4- { 5 -(etilsulfonil)-2- [(1 -metilpiperidin-4-il)oksi]fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,l,3-benzotiadiazol-4-iloksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-[2-(izokinolin-7-iloksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(2,5-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(3,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4-{5-(metilsulfonil)-2-[(l-okso-2,3-dihidro-lH-inden-4-il)oksi]fenil}- 1.6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(3,5-difIuorofenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4-[2-(4-metilfenoksi)-5-(metilsulfonil)fenil]-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4-[2-(2-metoksifenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4-{2-[(2-metilpiridin-3-il)oksi]-5-(metilsulfonil)fenil}-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-{2-[3-(dimetilamino)fenoksi]-5-(metilsulfonil)fenil}-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4- (5-(metilsulfonil)-2-[(l -okso-2,3-dihidro-1 H-inden-5-il)oksi]fenil} - 1.6- dihidro-7H-pirolo [2,3 -c]piridin-7-on; 6-metil-4-{5-(metilsulfonil)-2-[(3-okso-2,3-dihidro-lH-inden-5-il)oksi]fenil}- 1.6- dihidro-7H-pirolo [2,3 -c]piridin-7-on; 2-[2-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(metilsulfonil)fenoksi]benzonitril; 4-[2-(3-kloro-2-fluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4-[5-(metilsulfonil)-2-(naftalen-1 -iloksi)fenil]-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2-fluoro-5-metilfenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(5-fluoro-2-metilfenoksi)-5-(metilsulfoml)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4-[5-(metilsulfonil)-2-(kinolin-7-iloksi)fenil]-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4-[2-(4-kloro-3-fluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4-[5-(metilsuIfonil)-2-(piridin-3-iloksi)fenil]-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4-[2-(2,3-dihidro-lH-inden-5-iloksi)-5-(metilsuIfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 6-metil-4-{5-(metilsulfonil)-2-[4-(propan-2-il)fenoksi]fenil}-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(izokinolin-8-iloksi)-5-(metilsnlfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4-[5-(metilsulfonil)-2-(3,4,5-trifluorofenoksi)fenil]-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-(2-benzilfenil)-6-metil-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-(bifenil-2-il)-6-metil-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(l,4-dioksaspiro[4.5]dec-8-iloksi)-5-(etilsulfoml)feml]-6-metil-l,6-dihidro- 7H-pirolo[2,3-c]piridin-7-on; 4-[2-(ciklopropilmetoksi)-5-(etilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-{5-(etilsulfonil)-2-[(4-oksocikloheksil)oksi]fenil}-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-{2-[(ciklopropilmetil)amino]-5-(etilsulfonil)fenil}-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4- {5 -(metilsulfonil)-2- [(tetrahidrofuran-3 -ilmetil)amino]fenil} -1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-{5-(etilsulfonil)-2-[(cis-4-hidroksicikloheksil)oksi]fenil}-6-metil-l,6-dihidro- 7H-pirolo[2,3-c]piridin-7-on; 4- { 5-(etilsulfonil)-2-[(trans-4-hidroksicikloheksil)oksi]fenil} -6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 6-metil-4-[5-(metilsulfonil)-2-(tetrahidrofuran-3-iloksi)fenil]-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-{2-[(3-fluorooksetan-3-il)metoksi]-5-(metilsulfonil)fenil}-6-metil-l,6-dihidro- 7H-pirolo[2,3-c]piridin-7-on; 6-(ciklopropilmetoksi)-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)piridm-3-sulfbnamid; 6-(ciklopropilmetoksi)-N-metil-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)piridin-3-sulfonamid; 6-[(ciklopropilmetil)amino]-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)piridin-3 -sulfonamid; 6- [(ciklopropilmetil)amino]-N-metil-5-(6-metil-7 -okso-6,7 -dihidro-1H-pirolo[2,3-c]piridin-4-il)piridin-3-sulfonamid; 4-{5-(etilsulfonil)-2-[(cis-4-hidroksi-4-metilcikloheksil)oksi]fenil}-6-metil-l,6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-{5-(etilsulfonil)-2-[(trans-4-hidroksi-4-metilcikloheksil)oksi]fenil}-6-metil- l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(ciklobutiloksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4-[2-(ciklopentilmetoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(cikloheksiloksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4-[2-(ciklopentiloksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 6-metil-4-[5-(metilsulfonil)-2-(tetrahidrofuran-3-ilmetoksi)fenil]-l,6-dihidro- 7H-pirolo[2,3-c]piridin-7-on; 6-metil-4- {5-(metilsulfonil)-2-[2-(2-oksoimidazolidin-1 -il)etoksi]fenil}-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2-ciklopropiletoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(cikloheptiloksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 6-metil-4-[2-(2-metilpropoksi)-5-(metilsulfonil)fenil]-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 6-metil-4-[2-{ [(2S)-1 -metilpirolidin-2-il]metoksi} -5-(metilsulfonil)fenil]-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 6-metil-4- {2- [(2-metilciklopropil)metoksi]-5-(metilsulfonil)fenil} -1,6-dihidro-7H-pirolo[2,3 -c]piridin-7 -on; 4-[2-(cikloheksilmetoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4-{2-[2-(l-metilpirolidin-2-il)etoksi]-5-(metilsulfonil)fenil}-l,6-dihidro- 7H-pirolo[2,3-c]piridin-7-on; 6-metil-4- [5 -(metilsulfonil)-2- {[(2R)-5-oksopirolidin-2-il]metoksi} fenil] -1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 6-metil-4-{5-(metilsulfonil)-2-[2-(morfolin-4-il)etoksi]fenil}-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-metil-4-[5-(metilsulfonil)-2-{[(2S)-5-oksopirolidin-2-il]metoksi}fenil]-l,6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4- {2- [(1 -tert-butoksipropan-2-il)oksi] -5 -(metilsulfonil)fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4- {2-[( 1 S,4R)-biciklo[2.2.1 ]hept-2-ilmetoksi]-5-(metilsulfonil)fenil} -6-metil- l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 6-metil-4- {2- [(1 -metilciklopropil)metoksi] -5 -(metilsulfonil)fenil} -1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 6-metil-4- {5 -(metilsulfonil)-2- [2-(2-oksopirolidin-1 -il)etoksi]fenil} -1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 6-metil-4- {2- [(4-metilcikloheksil)oksi]-5 -(metilsulfonil)fenil} -1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(ciklobutilmetoksi)-5-(metilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]ciklopropansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-2-metoksietansulfonamid; 6-metil-4- {5-(metilsulfonil)-2-[triciklo[3.3.1.13,7]dec-2-iloksi]fenil} -1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-[(ciklopropilmetil)amino]-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)benzenesulfonamid; 4-[(ciklopropilmetil)amino] -N -metil-3 -(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)benzenesulfonamid; 4-{2-[(2,2-difluorociklopropil)metoksi]-5-(etilsulfonil)fenil}-6-metil-l,6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-(4-bromo-2-metoksifenil)-6-metil-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 6-(2,4-difluorofenoksi)-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)piridin-3-sulfonamid; 4- {2-(ciklopropilmetoksi)-5 - [(trifluorometil)sulfonil] fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4- {2- [(ciklopropilmetil)amino] -5 - [(trifluorometil)sulfonil]fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 6-[(ciklopropilmetil)amino]-N,N-dimetil-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo [2,3 -c]piridin-4-il)piridin-3 -sulfonamid; 6-(2,4-difluorofenoksi)-N-metil-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)piridin-3-sulfonamid; 4-[2-(ciklopropilmetoksi)-6-metilfenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4- {5-(etilsulfonil)-2- [(cis-4-metoksicikloheksil)oksi]fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-(ciklopropilmetoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)benzenesulfonamid; 4-(ciklopropilmetoksi)-N-metil-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)benzenesulfonamid; N-[4-(ciklopropilmetoksi)-2-metil-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]etansulfonamid; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-7-okso-6,7-dihidro-1 H-pirolo [2,3-c]piridin-2-karboksamid; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-N-etil-6-metil-7-okso-6,7- dihidro-1 H-pirolo[2,3 -c]piridin-2-karboksamid; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfbnil)fenil]-6-metil-7-okso-N-(2,2,2- trifluoroetil)-6,7-dihidro-lH-pirolo[2,3-c]piridin-2-karboksamid; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-2-(morfolin-4- ilkarbonil)-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfbnil)fenil]-6-metil-2-[(4-metilpiperazin-l-il)karbonil]-1,6-diWdro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-7-okso-N-(l,3-tiazol-2-il)-6,7-dihidro-1 H-pirolo [2,3-c]piridin-2-karboksamid; etil 4-[2-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)-4-(metilsulfonil)fenoksi]piperidine-1 -karboksilat; 4- [2-etoksi-5 -(metilsulfonil)fenil] -6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7 -on; 4-{5-(etilsulfonil)-2-[(trans-4-metoksicikloheksil)oksi]fenil}-6-metil-l,6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4- {2-[(ciklopropilmetil)amino]-5 -(propan-2-ilsulfonil)fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; N-[4-(ciklopropilmetoksi)-2-metil-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]metansulfonamid; N-[4-(ciklopropilmetoksi)-2-metil-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]metansulfonamid; 4-[5-(etilsulfonil)-2-(tetrahidro-2H-tiopiran-4-iloksi)fenil]-6-metil-l,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4- {2-[(l, 1 -dioksidotetrahidro-2H-tiopiran-4-il)oksi]-5-(etilsulfonil)fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 6-(2,4-difluorofenoksi)-N,N-dimetil-5-(6-metil-7 -okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)piridin-3-sulfonamid; 4-[2-(ciklopropilamino)-5-(etilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4-(5 -(etilsulfonil)-2-(cis-4-metoksi-4-metilcikloheksiloksi)fenil)-6-metil-1H-pirolo [2,3 -c]piridin-7(6H)-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-N,N,6-trimetil-7-okso-6,7- dihidro-lH-pirolo[2,3-c]piridin-2-karboksamid; 6-metil-4-{5-(metilsulfonil)-2-[4-(metilsulfonil)fenoksi]fenil}-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(propan-2-ilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 6-(ciklopropilmetoksi)-N,N-dietil-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)piridin-3-sulfonamid; 4-(ciklopropilmetoksi)-N,N-dimetil-3-(6-metil-7-okso-6,7-dihidro-lH- pirolo[2,3-c]piridin-4-il)benzenesulfbnamid; 4- [2-(ciklopropilmetoksi)-5 -fluorofenil] -6-metil-1,6-dihidro-7H-pirolo [2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(trifluorometil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-2-(hidroksimetil)-6-metil-l,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-[2-(2,3-dihidro-1 H-inden-2-iloksi)-5-(metilsulfonil)fenil]-6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-2-(l -hidroksietil)-6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-2-[(dimetilamino)metil]-6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-2-(morfolin-4-ilmetil)- 1.6- dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-2-[(4-metilpiperazin-l- il)metil]-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-2-[(fenilaniino)metil]- 1.6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-2-[(l,3-tiazol-2-ilamino)metil]-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-2-[(tetrahidrofuran-3-ilamino)metil]-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(cikIopropilmetoksi)-5-(fenilsulfonil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(ciklopropilmetoksi)-5-(morfolin-4-ilsulfbnil)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-(2-(2,4-difluorofenoksi)-5-[(metilsulfonil)metil]fenil}-6-rnetil-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)piridin-3-il]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-2-[(piridin-3-iloksi)metil]-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[5-(ciklopropilsulfonil)-2-(2,4-difluorofenoksi)fenil]-6-metil-l,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-2-(prop-l-en-2-il)-l,6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(metilsulfonil)fenil]-6-metil-2-(fenoksimetil)-l,6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(morfolin-4-ilsulfonil)fenil]-6-metil-l,6-dihidro- 7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(etilsulfonil)piridin-3-il]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-2-(morfolin-4-il)etansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-N-[2-(dimetilamino)etil]etansulfonamid; 4- {2-(2,4-difluorofenoksi)-5-[(etilsnlfonil)metil]fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-(2-(2,4-difluorofenoksi)-5-[2-(etilsulfonil)propan-2-il]fenil}-6-metil-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(pirolidin-1 -ilsulfonil)fenil]-6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-2-(dimetilamino)etansuIfonamid; etil 4-[4-(etilsulfonil)-2-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)fenoksi]piperidine-1 -karboksilat; 4-[2-(ciklopropilmetoksi)-5-(pirolidin-l-ilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4- {2- [(1 -acetilpiperidin-4-il)oksi] -5 -(etilsulfonil)fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[4-(etilsulfonil)-2-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)fenoksi]benzonitril; 4-[2-(ciklopropilmetoksi)-5-(2,3-dihidro-1 H-indol-1 -ilsulfonil)fenil]-6-metil- 1.6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4- {2-(2,4-difluorofenoksi)-5-[(fenilsulfonil)metil]fenil} -6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-{2-[(2,2-difluorociklopropil)metoksi]-5-(pirolidin-l-ilsulfonil)fenil}-6-metil- 1.6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4- {2-(ciklopropilmetoksi)-5 - [(3,3 -difluoroazetidin-1 -il)sulfonil] fenil} -6-metil- 1.6- dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-{2-[2-(2-hidroksietil)fenoksi]-5-(metilsulfonil)fenil}-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(ciklopropilmetoksi)-5- {[3-(dimetilamino)pirolidin-1 -il]sulfonil) fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-(2-(2,4-difluorofenoksi)-5-[(metilsulfonil)metil]piridin-3-il}-6-metil-l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; tert-butil 4-[4-(etilsulfonil)-2-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)fenoksi]piperidtne-1 -karboksitate; 4-(ciklopropilmetoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)-N-fenilbenzenesulfonamid; 4-[2-(ciklopropilmetoksi)-5-(pirolidin-1 -ilmetil)fenil]-6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(ciklopropilmetoksi)-5-(piridin-3-il)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[2-(ciklopropilmetoksi)-5-(morfolin-4-ilmetil)fenil]-6-metil-l,6-dihidro,-7H- pirolo[2,3-c]piridin-7-on; 4-{5-(etilsulfonil)-2-[3-(Wdroksimetil)fenoksi]fenil}-6-metil-l,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-[2-(ciklopropilmetoksi)-5-( 1 -metil-1 H-pirazol-4-il)fenil]-6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(2,3-dihidro-lH-indol-l-ilsulfonil)fenil]-6-metil- l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; N-[2-ciano-4-(2,4-difluorofenoksi)-5-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]etansulfonamid; tert-butil 4-[4-(ciklopropibnetoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)fenil]-3,6-dihidropiridin-1 (2H)-karboksilat; 4-[5-(6-aminopiridin-3-il)-2-(ciklopropilmetoksi)fenil]-6-metil-l,6-dihidro-7H-piro! o [2,3-c]piridin-7-on; 4-{2-[(2,2-difluorociklopropil)metoksi]-5-(etilsulfonil)fenil}-6-metil-7-oksoN- (2,2,2-trifluoroetil)-6,7-dihidro-lH-pirolo[2,3-c]piridin-2-karboksamid; 4- {2- [(ciklopropilmetil)amino] -5- [(metilsulfonil)metil]fenil} -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; 4-{2-[(ciklopropilmetil)amino]-5-(metilsulfonil)fenil}-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-[5-(etilsulfonil)-2-(pirolidin-l-il)fenil]-6-metil-l,6-dihidro-7H-pirolo[2,3- c]piridin-7-on; 4- [5 -(etilsulfonil)-2-(4-metilpiperazin-1 -il)fenil] -6-metil-1,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-{2-[(4-fluorofeml)amino]-5-(metilsulfonil)fenil}-6-metil-l,6-dihidro-7H-pirolo [2,3 -c]piridin-7-on; 4-(ciklopropilmetoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4- il)-N-(piridin-3-ilmetil)benzenesulfonamid; 4-[4-(ciklopropilmetoksi)-3'-fluorobifenil-3-il]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; 4-{2-[(4-fluorofenil)amino]-5-[(metilsulfonil)metil]fenil}-6-metil-l,6-dihidro- 7H-pirolo[2,3-c]piridin-7-on; [4-(ciklopropilmetoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin- 4-il)fenil]acetonitril; N-{4-(2,4-difluorofenoksi)-3-[2-(hidroksimetil)-6-metil-7-okso-6,7-dihidro-lH-pirolo [2,3 -c]piridin-4-il] fenil} etansulfonamid; N-[4-(2,4-difluorofenoksi)-3-{6-metil-2-[(4-metilpiperazin-l-il)karbonil]-7- okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il}fenil]etansulfonamid; N-[4-(2,4-difluorofenoksi)-3-{6-metil-2-[(4-metilpiperazin-l-il)metil]-7-okso- 6.7- dihidro-1 H-pirolo[2,3-c]piridin-4-il} feniljetansulfonamid; 4- [2-(ciklopropilmetoksi)-5 -(1,2,3,6-tetrahidropiridin-4-il)fenil] -6-metil-1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-N-(2-metoksietil)etansulfonamid; N - [4-(2,4-difluorofenoksi)-3 -(6-metil-7-okso-6,7-dihidro-1 H-pirolo [2,3 - c]piridin-4-il)fenil]-N-(piridin-2-ilmetil)etansulfonamid; N-(ciklopropilmetil)-N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro- lH-pirolo[2,3-c]piridin-4-il)fenil]etansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-N-[2-(2-oksopirolidin-l-il)etil]etansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-N-(tetrahidrofuran-2-ilmetil)etansulfonamid; N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3- c]piridin-4-il)fenil]-N-(3,3,3 -trifluoropropil)etansulfonamid; 4-(ciklopropilmetoksi)-N-(4-fluorofenil)-3-(6-metil-7-okso-6,7-dihidro-lH- pirolo[2,3-c]piridin-4-il)benzenesulfonamid; 4-[2-(ciklopropilmetoksi)-5-(6-fluoropiridin-3-il)fenil]-6-metil-l,6-dihidro-7H- pirolo[2,3-c]piridin-7-on; N-[4-(2,4-difluorofenoksi)-3-(3-fonnil-6-metil-7-okso-6,7-dihidro-lH- pirolo[2,3-c]piridin-4-il)fenil]etansulfonamid; N-{4-(2,4-difluorofenoksi)-3-[6-metil-3-(morfolin-4-ilmetil)-7-okso-6,7-dihidro-1 H-pirolo[2,3-c]piridin-4-il]fenil} etansulfonamid; N-[4-(2,4-difluorofenoksi)-3-{6-metil-3-[(4-metilpiperazin-l-il)metil]-7-okso- 6.7- dihidro-1 H-pirolo [2,3 -c]piridin-4-il} fenil] etansulfonamid; 4- (2-[(ciklopropilmetil)amino]fenil} -6-metil-1,6-dihidro-7H-pirolo [2,3-c]piridin-7-on; 4'-(ciklopropilmetoksi)-3,-(6-metil-7-okso-6,7-dihidro-lH-pirolo[2,3-c]piridin-4-il)bifenil-3-karbonitril; in 4-{2-(ciklopropilmetoksi)-5-[(4-hidroksipiperidin-l-il)sulfonil]fenil}-6-metil- l,6-dihidro-7H-pirolo[2,3-c]piridin-7-on.
- 30. Spojina po zahtevku 28 ali njena farmacevtsko sprejemljiva sol, kjer Ry predstavlja metil.
- 31. Spojina po zahtevku 30 ali njena farmacevtsko sprejemljiva sol, kjer L1 predstavlja CH2, C(O), (CH2)mO ali (CH2)mN(Rz).
- 32. Spojina po zahtevku 30 ali njena farmacevtsko sprejemljiva sol, kjer L1 predstavlja (CH2)mO.
- 33. Spojina po zahtevku 32 ali njena farmacevtsko sprejemljiva sol, kjer G1 predstavlja Gla.
- 34. Spojina po zahtevku 33 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja aril neodvisno nesubstituiran ali substituiran z 1,2, 3,4 ali 5 Rw.
- 35. Spojina po zahtevku 33 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja fenil neodvisno nesubstituiran ali substituiran z 1,2, 3,4 ali 5 Rw.
- 36. Spojina po zahtevku 33 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja cikloalkil neodvisno nesubstituiran ali substituiran z 1,2, 3,4 ali 5 Rw.
- 37. Spojina po zahtevku 33 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja monocikličen cikloalkil neodvisno nesubstituiran ali substituiran z 1, 2, 3,4 ali 5 Rw.
- 38. Spojina po zahtevku 33 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja heterocikel neodvisno nesubstituiran ali substituiran z 1,2, 3,4 ali 5 Rw.
- 39. Spojina po zahtevku 33 ali njena farmacevtsko sprejemljiva sol, kjer Gla predstavlja monocikličen heterocikel neodvisno nesubstituiran ali substituiran z 1, 2, 3,4 ali 5 Rw.
- 40. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer Υ1 predstavlja CRU; X1 je N; X2 je CR*2; in Ry je metil.
- 41. Spojina po zahtevku 40 ali njena farmacevtsko sprejemljiva sol, kjer je spojina izbrana iz skupine, ki vsebuje N-[4-(2,4-difluorofenoksi)-3-(6-metil-7-okso-6,7-dihidro-lH-pirazolo[3,4- c]piridin-4-il)fenil]etansulfonamid; 4-(2-(2,4-difluorofenoksi)-5-[(metilsulfonil)metil]fenil}-6-metil-l,6-dihidro-7H-pirazolo[3,4-c]piridin-7-on; 4-[2-(2,4-difluorofenoksi)-5-(etilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirazolo[3,4-c]piridin-7-on; in 4-[2-(ciklopropilmetoksi)-5-(etilsulfonil)fenil]-6-metil-l,6-dihidro-7H-pirazolo[3,4-c]piridin-7-on; ali njihove farmacevtsko sprejemljive soli.
- 42. Spojin po kateremkoli zahtevku 16, od 18 do 28 in od 30 do 40 ali njena farmacevtsko sprejemljiva sol, kjer A1 predstavlja CR1, A2 je CR2, A3 je CR3 in A4 je CR4; ali eden izmed A1, A2, A3 in A4 je N.
- 43. Spojina po zahtevku 42 ali njena farmacevtsko sprejemljiva sol, kjer R2 predstavlja vodik, Ci-C6 alkil, N02, G2a, -S(0)2R2d, -S(0)2NR2bR2c, -C(0)R2d, -C(0)OR2a, -C(0)NR2bR2c, -NR2bR2c, -N(R2e)C(0)R2d, -N(R2e)S(0)2R2d, -N(R2e)S(0>2NR2bR2c,-(Ci-C6 alkilenil)-G2a, -(Ci-C6 alkilenil)-OR2a, -(C,-C6 alkilenil)-S(0)2R2d, -(C,-C6 alkilenil)-S(0)2NR2bR2c, -(Ci-C6 alkilenil)-C(0)R2d, -(Ci-C6 alkilenil)-C(0)OR2a, -(Ci-C6 alkilenil)-C(0)NR2bR2c, -(Ci-C6 alkilenil)- NR2bR2c, -(Ci-Ce alkilenil)-N(R2e)C(0)R2d, -(Ci-C6 alkilenil)-N(R2e)S(0)2R2d ali -(Ci-C6alkilenil)-N(R2e)S(0)2NR2bR2c. λ
- 44. Spojina po zahtevku 42 ali njena farmacevtsko sprejemljiva sol, kjer R predstavlja -S(0)2R2d, -S(0)2NR2bR2c, -N(R2e)S(0)2R2d ali -N(R2e)S(0)2NR2bR2c.
- 45. Spojina po zahtevku 44 ali njena farmacevtsko sprejemljiva sol, kjer Rx predstavlja vodik ali metil.
- 46. Spojina po zahtevku 44 ali njena farmacevtsko sprejemljiva sol, kjer Rx predstavlja vodik.
- 47. Spojina po zahtevku 46 ali njena farmacevtsko sprejemljiva sol, kjer Rxl predstavlja vodik, -ClOjOR8*1, -C(0)NRbxlRcxl, Gxl ali Cj-C6 alkil, kjer je Ci-C6 alkil neobvezno substituiran z OR8*1.
- 48. Spojina po zahtevku 46 ali njena farmacevtsko sprejemljiva sol, kjer Rxl predstavlja vodik, -CiOjOR8*1 ali -C(0)NRbxlRcxl.
- 49. Spojina po zahtevku 48 ali njena farmacevtsko sprejemljiva sol, kjer R*2 predstavlja vodik.
- 50. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer Rx predstavlja vodik; Ry je metil; Υ1 je CRU, kjer Ru predstavlja vodik; X1 je CRxl, kjer Rxl predstavlja vodik ali -C(0)NRbxlRcxl; X2 je CRx2, kjer R*2 predstavlja vodik; L1 je (CH2)mO, kjer je m enako 0; G1 je Gla ali -(C1-C6 alkilenil)-Gla, kjer je Gla neobvezno substituiran fenil ali neobvezno substituiran cikloalkil; in R2 je -S(0)2R2d, -S(0)2NR2bR2c, -N(R2e)S(0)2R2d ali -(Ci-C6 alkilenil)-S(0)2R2d.
- 51. Spojina po zahtevku 50 ali njena farmacevtsko sprejemljiva sol, kjer A1 predstavlja CR1, A2 is CR2, A3 is CR3 in A4 is CR4.
- 52. Spojina po zahtevku 50 ali njena farmacevtsko sprejemljiva sol, kjer A1 predstavlja CR1, A2 je CR2, A3 je CR3 in A4 je N.
- 53. Spojina po zahtevku 1 ali njena farmacevtsko sprejemljiva sol, kjer Rx predstavlja vodik; Ry je metil; Υ1 je CRU, kjer Ru predstavlja vodik; X1 je CRxl, kjer Rxl predstavlja vodik; X2 je CRx2, kjer R*2 predstavlja vodik; L1 je (CH2)mN(Rz), kjer je m enako 0 in Rz predstavlja vodik; G1 je -(Ci-C6 alkilenil)-Gla, kjer je Gla neobvezno substituiran cikloalkil; in R2 je -S(0)2R2d, -S(0)2NR2bR2c, -N(R2e)S(0)2R2d ali -(Ci-C6 alkilenil)-S(0)2R2d.
- 54. Spojina po zahtevku 53 ali njena farmacevtsko sprejemljiva sol, kjer A1 predstavlja CR1, A2 je CR2, A3 je CR3 in A4 je CR4.
- 55. Farmacevtski sestavek, ki vsebuje terapevtsko učinkovito količino spojine s formulo (I) po zahtevku 1 ali njene farmacevtsko sprejemljive soli v kombinaciji s farmacevtsko sprejemljivim nosilcem.
- 56. Spojina s formulo (I) po zahtevku 1 ali njena farmacevtsko sprejemljiva sol za uporabo v postopku zdravljenja raka v subjektu, kjer omenjeni postopek obsega administracijo terapevtsko učinkovito količino spojine s formulo (I) po zahtevku 1 ali njene farmacevtsko sprejemljive soli subjektu, ki jo potrebuje.
- 57. Spojina za uporabo po zahtevku 56, kjer je rak izbran iz skupine, ki vsebuje: akustično neuromo, akutno levkemijo, akutno limfocitno levkemijo, akutno mielocitno levkemijo (monocitna, mieloblastna, adenokarcinom, angiosarkom, astrocitom, mielomonocitna in promielocitna), akutno levkemijo t-celic, karcinom bazalnih celic, karcinom žolčnega kanala, rak mehurja, možganski rak, rak dojke, bronhogenski karcinom, rak materničnega vratu, hondrosarkom, hordom, horiokarcinom, kronično levkemijo, kronično limfocitno levkemijo, kronično mielocitno (granulocitno) levkemijo, kronično mielogeno levkemijo, črevesni rak, kolorektalni rak, kraniofaringiom, cistadenokarcinom, difuzni velikocelični B limfom, disproliferativne spremembe (displazije in metaplazije), embrionalni karcinom, rak endometrija, sarkom endotelija, ependimom, rak epitelija, eritrolevkemijo, ezofagični rak, na estrogenski receptor pozitiven rak dojke, esencialno trombocitemijo, Evvingov tumor, fibrosarkom, folikulami limfom, rak testisov na zarodnih celicah, gliom, glioblastom, gliosarkom, bolezen težke verige, hemangioblastom, hepatom, hepatocelulami rak, hormonsko neobčutljiv rak prostate, leiomiosarkom, levkemijo, liposarkom, pljučni rak, limfagioendoteliosarkom, limfangiosarkom, limfoblastno levkemijo, limfom (Hodgkinsov in ne-Hodgkinsov), malignosti in hiperproliferativne motnje mehurja, dojke, črevesja, pljuč, jajčnikov, trebušne slinavke, prostate, kože in maternice uterus, limfoidne malignosti, ki izvorajo iz T-celic ali B-celic, levkemijo, limfom, medulami karcinom, meduloblastom, melanom, meningiom, mezoteliom, multipli mielom, mielogeno levkemijo, mielom, miksosarkom, nevroblastom, NUT karcinom (NMC), nedrobno celični plučni rak, oligodendrogliom, rak ustne votline, osteogeni sarkom, rak jajčnikov, rak trebušne slinavke, papilarne adenokarcinome, papilarni karcinom, pinealom, policitemia vera, rak prostate, rektalni rak, karcinom ledvičnih celic, retinoblastom, rabdomiosarkom, sarkom, karcinom lojnice, seminom, kožni rak, drobnocelični pljučni karcinom, trdni tumorji (karcinomi in sarkomi), drobnocelični pljučni rak, trebušni rak, karcinom skvamozih celic, sinoviom, karcinom znojnih žlez, rak ščitnice, Waldenstromovo makroglobulinemijo, testikulami tumorji, rak maternice in Wilmsov tumor.
- 58. Spojina za uporabo po zahtevku 56, kjer omenjeni postopek nadalje obsega administracijo terapevtsko učinkovite količine vsaj enega dodatnega terapevtskega sredstva, kjer je dodatno terapevtsko sredstvo izbrano iz skupine, ki vsebuje citarabin, bortezomib in 5-azacitidin.
- 59. Spojina s formulo (I) po zahtevku 1 ali njena farmacevtsko sprejemljiva sol za uporabo v postopku zdravljenja bolezni ali stanja v subjektu, kjer omenjeni postopek obsega administracijo terapevtsko učinkovite količine spojine s formulo (I) po zahtevku 1 ali njene farmacevtsko sprejemljive soli subjektu, ki jo potrebuje, kjer je omenjena bolezen ali stanje izbrana iz skupine, ki vsebuje: Addisonovo bolezen, akutni protin, ankilozirajoči spondilitis, astmo, aterosklerozo, Behcetovo bolezen, bulozne kožne bolezni, kronično obstruktivno pljučno bolezen (COPD), Crohnovo bolezen,dermatitis, ekcem, arteritis velikanskih celic, glomerulonefritis, hepatitis, hipofizitis, vnetna črevesna bolezen, Kawasakijeva bolezen, lupus nefritis, multiplo sklerozo, miokarditis, miozitis, nefritis, zavrnitev transplantacije organa, osteoartritis, pankreatitis, perikarditis, nodozni poliarteritis, pnevmonitis, primarno žolčno cirozo, psoriazo, psoriatični artritis, revmatoidni artritis, skleritis, sklerozirajoč holangitis, sepso, lupus eritematozus, Takayasujev arteritis, toksični šok, tiroiditis, diabetes tipa I, ulcerozni kolitis, uveitis, vitiligo, vaskulitis in Wegenerjevo granulomatozo.
- 60. Spojina s formulo (I) po zahtevku 1 ali njena farmacevtsko sprejemljiva sol za uporabo v postopku zdravljenja bolezni ali stanja v subjektu, kjer omenjeni postopek obsega administracijo terapevtsko učinkovite količine spojine s formulo (I) po zahtevku 1 ali njene farmacevtsko sprejemljive soli subjektu, ki jo potrebuje, kjer je omenjena bolezen ali stanje izbrana iz skupine, ki vsebuje: diabetično nefropatijo, hipertenzivno nefropatijo, s HIV povezano nefropatijo, glomerulonefritis, lupus nefritis, IgA nefropatijo, žariščno segmentno glomerulosklerozo, membranski glomerulonefritis, bolezen minimalnih sprememb, policistično ledvično bolezen in tubulointersticijski nefritis.
- 61. Spojina s formulo (I) po zahtevku 1 ali njena farmacevtsko sprejemljiva sol za uporabo v postopku zdravljenja akutne ledvične bolezni ali stanja v subjektu, kjer omenjeni postopek obsega administracijo terapevtsko učinkovite količine spojine s formulo (I) po zahtevku 1 ali njene farmacevtsko sprejemljive soli subjektu, ki jo potrebuje, kjer je omenjena bolezen ali stanje izbrana iz skupine, ki vsebuje bolezni povzročene z ishemijo-reperfuzijo, s srčnim in drugim večjim kirurškim posegom, s perkutano koronarno intervencijo, z radijskim kontrastnim sredstvom, s sepso, s pljučnico in s toksičnostjo drog.
- 62. Spojina s formulo (I) po zahtevku 1 ali njena farmacevtsko sprejemljiva sol za uporabo v postopku zdravljenja sindroma pridobljene imunske pomanjkljivosti (AIDS) v subjektu, kjer omenjeni postopek obsega administracijo terapevtsko učinkovite količine spojine s formulo (I) po zahtevku 1 ali njene farmacevtsko sprejemljive soli subjektu, ki jo potrebuje.
- 63. Spojina s formulo (I) po zahtevku 1 ali njena farmacevtsko sprejemljiva sol za uporabo v postopku zdravljenja bolezni ali stanja v subjektu, kjer omenjeni postopek obsega administracijo terapevtsko učinkovite količine spojine s formulo (I) po zahtevku 1 ali njene farmacevtsko sprejemljive soli subjektu, ki jo potrebuje, kjer je omenjena bolezen ali stanje izbrana iz skupine, ki vsebuje: debelost, dislipidemijo, hiperholesterolemijo, Alzheimerjevo bolezen, metabolni sindrom, jetrno steatozo, insulinsko rezistenco pri diabetesu tipa II, diabetično retinopatijo in diabetično nevropatijo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2011/002224 WO2013097052A1 (en) | 2011-12-30 | 2011-12-30 | Bromodomain inhibitors |
PCT/CN2012/086357 WO2013097601A1 (en) | 2011-12-30 | 2012-12-11 | Bromodomain inhibitors |
EP12863599.2A EP2797918B1 (en) | 2011-12-30 | 2012-12-11 | Bromodomain inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2797918T1 true SI2797918T1 (sl) | 2018-05-31 |
Family
ID=48696151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201231242T SI2797918T1 (sl) | 2011-12-30 | 2012-12-11 | Inhibitorji bromodomene |
Country Status (39)
Country | Link |
---|---|
US (5) | US9296741B2 (sl) |
EP (2) | EP2797918B1 (sl) |
JP (3) | JP6117238B2 (sl) |
KR (1) | KR102008975B1 (sl) |
CN (2) | CN104136435B (sl) |
AR (2) | AR089527A1 (sl) |
AU (3) | AU2012361967B2 (sl) |
BR (1) | BR112014016233B1 (sl) |
CA (1) | CA2859619C (sl) |
CL (1) | CL2014001752A1 (sl) |
CO (1) | CO7020912A2 (sl) |
CR (1) | CR20140332A (sl) |
CY (1) | CY1120287T1 (sl) |
DK (1) | DK2797918T3 (sl) |
DO (1) | DOP2014000152A (sl) |
EC (1) | ECSP14011359A (sl) |
ES (1) | ES2665890T3 (sl) |
GT (1) | GT201400133A (sl) |
HK (3) | HK1203508A1 (sl) |
HR (1) | HRP20180357T1 (sl) |
HU (1) | HUE038391T2 (sl) |
IL (1) | IL233454A (sl) |
LT (1) | LT2797918T (sl) |
ME (1) | ME03028B (sl) |
MX (1) | MX341740B (sl) |
NO (1) | NO2797918T3 (sl) |
PE (1) | PE20142340A1 (sl) |
PH (1) | PH12014501469A1 (sl) |
PL (1) | PL2797918T3 (sl) |
PT (1) | PT2797918T (sl) |
RS (1) | RS56978B1 (sl) |
RU (3) | RU2671571C1 (sl) |
SG (1) | SG11201403717WA (sl) |
SI (1) | SI2797918T1 (sl) |
TW (1) | TWI602815B (sl) |
UA (1) | UA111770C2 (sl) |
UY (2) | UY34559A (sl) |
WO (2) | WO2013097052A1 (sl) |
ZA (1) | ZA201404616B (sl) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2569434B1 (en) | 2010-05-14 | 2019-09-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia and related disorders |
HUE031073T2 (en) | 2010-05-14 | 2017-06-28 | Dana Farber Cancer Inst Inc | Thieno triazolo-diazepine compounds for the treatment of neoplasia |
US9301962B2 (en) | 2010-05-14 | 2016-04-05 | Baylor College Of Medicine | Male contraceptive compositions and methods of use |
WO2012154760A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
NO3175985T3 (sl) | 2011-07-01 | 2018-04-28 | ||
TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
JP6171003B2 (ja) | 2012-05-24 | 2017-07-26 | ノバルティス アーゲー | ピロロピロリジノン化合物 |
WO2014078257A1 (en) | 2012-11-14 | 2014-05-22 | Glaxosmithkline Llc | Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
KR20150096794A (ko) | 2012-12-21 | 2015-08-25 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물 |
US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
AU2014249192B2 (en) | 2013-03-11 | 2017-12-21 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
ES2654362T3 (es) | 2013-03-14 | 2018-02-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Furopiridinas como inhibidores de bromodominio |
US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
BR112015023184A2 (pt) | 2013-03-15 | 2017-11-21 | Constellation Pharmaceuticals Inc | método para o tratamento de uma doença, inibidor e seu uso, composição, método de identificação de um composto e método para inibir a produção de il-4, il-5 e il-13 |
EP2970282B1 (en) | 2013-03-15 | 2019-08-21 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
MX2015016344A (es) | 2013-05-27 | 2016-03-01 | Novartis Ag | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. |
BR112015029353A2 (pt) | 2013-05-28 | 2017-07-25 | Novartis Ag | derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças |
US9624247B2 (en) | 2013-05-28 | 2017-04-18 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
CN109939113B (zh) | 2013-06-21 | 2022-02-15 | 恒翼生物医药科技(上海)有限公司 | 双环溴结构域抑制剂 |
US9636328B2 (en) | 2013-06-21 | 2017-05-02 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
AR096758A1 (es) * | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
CN105518007A (zh) * | 2013-06-28 | 2016-04-20 | 艾伯维公司 | 布罗莫结构域抑制剂 |
EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
KR20160034379A (ko) | 2013-07-25 | 2016-03-29 | 다나-파버 캔서 인스티튜트 인크. | 전사 인자의 억제제 및 그의 용도 |
CA2919948C (en) | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
PL3640241T3 (pl) * | 2013-10-18 | 2022-12-05 | Celgene Quanticel Research, Inc. | Inhibitory bromodomeny |
WO2015070020A2 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
US9550796B2 (en) | 2013-11-21 | 2017-01-24 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as BET inhibitors |
WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
WO2015081246A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015081280A1 (en) * | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
AU2014363989A1 (en) * | 2013-12-09 | 2016-06-16 | Abbvie Inc. | Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors |
AU2014361381A1 (en) * | 2013-12-10 | 2016-06-16 | Abbvie Inc. | Bromodomain inhibitors |
WO2015092118A1 (en) * | 2013-12-17 | 2015-06-25 | Orion Corporation | Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
CA2936865A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
EP3099693A4 (en) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
WO2015117083A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
AU2015222805B2 (en) | 2014-02-28 | 2020-05-21 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
JP2017511801A (ja) | 2014-02-28 | 2017-04-27 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | BETブロモドメイン阻害剤としての9H−ピリミド[4,5−b]インドールおよび関連類似体 |
US10246455B2 (en) * | 2014-04-11 | 2019-04-02 | Taipei Medical University | Histone deacetylase inhibitors |
MY180775A (en) * | 2014-04-23 | 2020-12-09 | Incyte Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
US20150345047A1 (en) * | 2014-05-29 | 2015-12-03 | Memorial Sloan Kettering Cancer Center | Systems and methods for identifying drug combinations for reduced drug resistance in cancer treatment |
CA2955077A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
CN106715437A (zh) | 2014-08-08 | 2017-05-24 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Betタンパク質阻害剤として用いるための三環式複素環化合物 |
BR112017008714A2 (pt) | 2014-10-27 | 2017-12-19 | Tensha Therapeutics Inc | inibidores de bromodomínio |
WO2016077375A1 (en) * | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
MA40943A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
EP3632915A1 (en) * | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
EP3250571B1 (en) | 2015-01-29 | 2022-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
WO2016138332A1 (en) | 2015-02-27 | 2016-09-01 | The Regents Of The University Of Michigan | 9h-pyrimido [4,5-b] indoles as bet bromodomain inhibitors |
GB201503720D0 (en) * | 2015-03-05 | 2015-04-22 | Glaxosmithkline Ip No 2 Ltd | Chemical compound |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
WO2016168565A1 (en) * | 2015-04-16 | 2016-10-20 | President And Fellows Of Harvard College | Methods for treatment of chronic obstructive pulmonary disease and/or therapy monitoring |
TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CA2989265A1 (en) * | 2015-07-02 | 2017-01-05 | Orion Corporation | Bicyclic heterocycle derivatives as bromodomain inhibitors |
WO2017027571A1 (en) | 2015-08-10 | 2017-02-16 | Dana-Farber Cancer Institute, Inc. | Mechanism of resistance to bet bromodomain inhibitors |
PE20181086A1 (es) | 2015-09-11 | 2018-07-05 | Dana Farber Cancer Inst Inc | Acetamida tienotrizolodiazepinas y usos de las mismas |
WO2017044849A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
CN105254635A (zh) * | 2015-10-30 | 2016-01-20 | 中国药科大学 | 一类咪唑并吡嗪类化合物及其药物组合物和用途 |
SG10201913450PA (en) | 2015-11-25 | 2020-03-30 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibitors and uses thereof |
CN108602821B (zh) * | 2015-12-14 | 2021-06-29 | 恒元生物医药科技(苏州)有限公司 | 1h-咪唑并[4,5-b]吡啶基bet溴结构域抑制剂 |
US20190040063A1 (en) * | 2016-02-05 | 2019-02-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tricyclic compound for bromodomain-containing protein inhibitor and preparation pharmaceutical composition, and application thereof |
CN109071562B (zh) | 2016-02-15 | 2022-03-22 | 密执安大学评议会 | 作为bet溴结构域抑制剂的稠合1,4-氧氮杂䓬和相关类似物 |
SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
US10633386B2 (en) | 2016-04-12 | 2020-04-28 | The Regents Of The University Of Michigan | BET protein degraders |
RU2741808C2 (ru) * | 2016-04-15 | 2021-01-28 | Эббви Инк. | Ингибиторы бромодомена |
EP3464286B1 (en) | 2016-05-24 | 2021-08-18 | Genentech, Inc. | Pyrazolopyridine derivatives for the treatment of cancer |
EP4234554A3 (en) | 2016-06-20 | 2023-12-27 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
US11466028B2 (en) | 2016-09-13 | 2022-10-11 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as BET protein degraders |
WO2018052949A1 (en) | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet protein degraders |
EP3825313A1 (en) * | 2016-10-14 | 2021-05-26 | AbbVie Inc. | Pyridin-2(1h)-one derivatives as bromodomain inhibitors |
CA3039003A1 (en) * | 2016-10-14 | 2018-04-19 | Abbvie Inc. | Bromodomain inhibitors |
CN108069958A (zh) * | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
RU2019117356A (ru) | 2016-11-10 | 2020-12-10 | Лосинь Фармасьютикал (Шанхай) Ко., Лтд. | Азотсодержащее макроциклическое соединение, способ его получения, фармацевтическая композиция и применение |
TW201825490A (zh) * | 2017-01-11 | 2018-07-16 | 大陸商江蘇豪森藥業集團有限公司 | 吡咯並[2,3-c]吡啶類衍生物、其製備方法及其在醫藥上的應用 |
CN110198941B (zh) * | 2017-01-25 | 2021-09-28 | 江苏豪森药业集团有限公司 | 吡咯并吡啶类n-氧化衍生物及其制备方法和应用 |
WO2018144789A1 (en) | 2017-02-03 | 2018-08-09 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
CN108627577A (zh) * | 2017-03-17 | 2018-10-09 | 武汉宏韧生物医药科技有限公司 | 一种人血浆中小檗碱含量的定量检测方法 |
US20210130346A1 (en) * | 2017-04-14 | 2021-05-06 | Abbvie Inc. | Bromodomain Inhibitors |
CN108976278B (zh) * | 2017-06-05 | 2021-04-06 | 海创药业股份有限公司 | 一种嵌合分子及其制备和应用 |
CN109384784B (zh) * | 2017-08-10 | 2021-01-12 | 浙江海正药业股份有限公司 | 磺酰胺类衍生物、其制备方法及其在医药上的用途 |
CN109384785B (zh) * | 2017-08-10 | 2021-09-28 | 浙江海正药业股份有限公司 | 吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途 |
CA3073543A1 (en) * | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
WO2019055444A1 (en) | 2017-09-13 | 2019-03-21 | The Regents Of The University Of Michigan | DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS |
CN110041333B (zh) | 2018-01-16 | 2022-03-01 | 中国科学院上海药物研究所 | 溴结构域抑制剂化合物及其用途 |
WO2019184919A1 (zh) * | 2018-03-27 | 2019-10-03 | 成都海创药业有限公司 | 一种含有金刚烷的化合物及其在治疗癌症中的用途 |
US10442799B1 (en) | 2018-04-07 | 2019-10-15 | Fuqiang Ruan | Heterocyclic compounds and uses thereof |
WO2019222331A1 (en) * | 2018-05-15 | 2019-11-21 | Abbvie Inc. | Treating solid tumors with bromodomain inhibitors |
CN110577526B (zh) * | 2018-06-07 | 2023-10-27 | 上海翰森生物医药科技有限公司 | 溴域结构蛋白抑制剂的盐及其制备方法和应用 |
CN110372693B (zh) * | 2018-07-04 | 2022-05-03 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
CA3106733A1 (en) | 2018-07-25 | 2020-01-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Sulfoximine compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof |
CN110776508B (zh) * | 2018-07-27 | 2021-07-16 | 海创药业股份有限公司 | 一种brd4抑制剂及其制备方法和用途 |
TWI816881B (zh) * | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥(上海)股份有限公司 | 用於治療三陰性乳癌之組合療法 |
AU2019372121A1 (en) | 2018-10-30 | 2021-05-27 | Nuvation Bio Inc. | Heterocyclic compounds as BET inhibitors |
CN111377934B (zh) * | 2018-12-29 | 2023-01-24 | 中国科学院上海药物研究所 | 一类杂环化合物,其制备及用途 |
CA3133131A1 (en) * | 2019-03-17 | 2020-09-24 | Shanghai Ringene Biopharma Co., Ltd. | Pyrrole amidopyridone compound, preparation method therefor and use thereof |
GB201905721D0 (en) * | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
WO2020232214A1 (en) * | 2019-05-14 | 2020-11-19 | Abbvie Inc. | Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor |
WO2020253711A1 (zh) * | 2019-06-17 | 2020-12-24 | 中国科学院上海药物研究所 | 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途 |
AU2020299592A1 (en) | 2019-07-02 | 2022-02-17 | Nuvation Bio Inc. | Heterocyclic compounds as BET inhibitors |
EP4092027A4 (en) * | 2020-01-19 | 2024-02-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | CRYSTAL FORM AND SALT FORM OF A BROMODOMAIN PROTEIN INHIBITOR AND METHOD FOR THE PRODUCTION THEREOF |
CN115279370A (zh) | 2020-03-05 | 2022-11-01 | C4医药公司 | 用于brd9的靶向降解的化合物 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022012456A1 (en) * | 2020-07-17 | 2022-01-20 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Novel heterocyclic compounds as bet inhibitors |
GB202016977D0 (en) | 2020-10-26 | 2020-12-09 | In4Derm Ltd | Compounds |
WO2022116968A1 (zh) * | 2020-12-01 | 2022-06-09 | 成都苑东生物制药股份有限公司 | 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途 |
CN117460732A (zh) * | 2021-06-11 | 2024-01-26 | 杭州中美华东制药有限公司 | 吡咯并吡啶酮类化合物及其制备方法和用途 |
AU2022303310A1 (en) | 2021-06-29 | 2024-02-08 | Tay Therapeutics Limited | Pyrrolopyridone derivatives useful in the treatment of cancer |
WO2023274418A1 (zh) * | 2021-07-02 | 2023-01-05 | 南京明德新药研发有限公司 | 蛋白降解靶向嵌合体类化合物 |
CN115611890B (zh) * | 2021-07-15 | 2024-05-31 | 成都硕德药业有限公司 | 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途 |
CN116554171A (zh) * | 2022-05-30 | 2023-08-08 | 成都苑东生物制药股份有限公司 | 一种brd4抑制剂类化合物的新晶型、用途及其制备方法 |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1507957A (en) | 1975-03-25 | 1978-04-19 | Byk Gulden Lomberg Chem Fab | Nitrofuryl-pyrazole derivatives methods for producing them and medicaments comprising them |
US4072746A (en) | 1975-10-14 | 1978-02-07 | Sterling Drug Inc. | 3-Amino-5-(pyridinyl)-2(1H)-pyridinones |
US4004012A (en) | 1975-10-14 | 1977-01-18 | Sterling Drug Inc. | 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones |
DE2845456A1 (de) | 1978-10-19 | 1980-08-14 | Merck Patent Gmbh | 6-arylpyridazin-3-one und verfahren zu ihrer herstellung |
US4298609A (en) | 1979-08-30 | 1981-11-03 | Sterling Drug Inc. | 4,5-Dihydro-6-(4-pyridinyl)-3-pyridazinol and salts, their preparation and use as blood pressure lowering agents |
FR2478640A1 (fr) | 1980-03-24 | 1981-09-25 | Sanofi Sa | Nouvelles thieno (2,3-d) pyridazinones-4 et thieno (2,3-d) pyridazinones-7, leur procede de preparation et leur therapeutique |
US4305943A (en) | 1980-04-28 | 1981-12-15 | Sterling Drug Inc. | 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics |
US4486431A (en) | 1981-01-14 | 1984-12-04 | Sterling Drug Inc. | Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones |
US4338446A (en) | 1980-04-28 | 1982-07-06 | Sterling Drug Inc. | Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates |
US4304776A (en) | 1980-04-28 | 1981-12-08 | Sterling Drug Inc. | 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics |
US4346221A (en) | 1980-04-28 | 1982-08-24 | Sterling Drug Inc. | Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones |
US4337253A (en) | 1980-04-28 | 1982-06-29 | Sterling Drug Inc. | 4,5-Dihydro-2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone and its use as a cardiotonic |
US4559352A (en) | 1981-03-30 | 1985-12-17 | Sterling Drug Inc. | 1,2-Dihydro-2-oxo-5-(hydroxy-and/or amino-phenyl)-nicotinonitriles and cardiotonic use thereof |
US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
US4404203A (en) | 1981-05-14 | 1983-09-13 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
US4465686A (en) | 1981-09-08 | 1984-08-14 | Sterling Drug Inc. | 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation |
US4515797A (en) | 1981-09-08 | 1985-05-07 | Sterling Drug Inc. | 3-Amino-5-(hydroxy- and/or aminophenyl)-6-(lower-alkyl)-2(1H)-pyridinones and cardiotonic use thereof |
US4353905A (en) | 1981-09-17 | 1982-10-12 | Warner-Lambert Company | Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones |
US4599423A (en) | 1982-04-26 | 1986-07-08 | Sterling Drug Inc. | Preparation of 5-(hydroxy- and/or aminophenyl-6-lower-alkyl)-2(1H)-pyridinones |
US4734415A (en) | 1982-08-13 | 1988-03-29 | Warner-Lambert Company | Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones |
DE3241102A1 (de) | 1982-11-06 | 1984-05-10 | A. Nattermann & Cie GmbH, 5000 Köln | Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung |
DE3321012A1 (de) | 1983-06-10 | 1984-12-13 | A. Nattermann & Cie GmbH, 5000 Köln | Substituierte 4,5-dihydro-6-(thien-2-yl)-3(2h)-pyridazinone und 6-(thien-2-yl)-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung |
US4666902A (en) | 1983-06-20 | 1987-05-19 | Cassella Aktiengesellschaft | Tetrahydropyridazinone derivatives, processes for their preparation and their use |
GB8323553D0 (en) | 1983-09-02 | 1983-10-05 | Smith Kline French Lab | Pharmaceutical compositions |
US4816454A (en) | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
US5192563A (en) | 1986-10-22 | 1993-03-09 | Wm. Wrigley, Jr. Company | Strongly mint-flavored chewing gums with reduced bitterness and harshness |
US5112625A (en) | 1989-02-15 | 1992-05-12 | Wm. Wrigley Jr. Company | Aqueous zein coated sweeteners and other ingredients for chewing gum |
US4863745A (en) | 1986-10-22 | 1989-09-05 | Wm. Wrigley Jr. Company | Chewing gum containing zein coated high-potency sweetener and method |
US5217735A (en) | 1986-10-22 | 1993-06-08 | Wm. Wrigley Jr. Company | Method of making chewing gum with delayed release ingredients |
US5221543A (en) | 1986-10-22 | 1993-06-22 | Firma Wilhelm Fette Gmbh | Method of making a fast release stabilized aspartame ingredient for chewing gum |
US4908371A (en) | 1987-11-10 | 1990-03-13 | Ciba-Geigy Corporation | Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload |
US4919941A (en) | 1987-12-18 | 1990-04-24 | Wm. Wrigley Jr. Company | Chewing gum containing delayed release protein sweetener and method |
DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
AU7238191A (en) | 1990-02-19 | 1991-09-03 | Chugai Seiyaku Kabushiki Kaisha | Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom |
DE4023369A1 (de) | 1990-07-23 | 1992-01-30 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
ES2131506T3 (es) | 1990-09-21 | 1999-08-01 | Rohm & Haas | Dihidropiridacinonas y piridacinonas como fungicidas. |
WO1992006087A1 (fr) | 1990-10-02 | 1992-04-16 | Kaken Pharmaceutical Co., Ltd. | Derive d'ethynylphenyle a substitution pyridazinone et medicament contre les affections des organes circulatoires contenant ce derive en tant qu'ingredient actif |
DE4127404A1 (de) | 1991-08-19 | 1993-02-25 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
CN1038249C (zh) | 1991-08-28 | 1998-05-06 | 罗姆和哈斯公司 | 含有二氢哒嗪酮及其相关化合物的杀菌组合物 |
DE69229874T2 (de) | 1991-10-09 | 1999-12-09 | Syntex Inc | Pyrido pyridazinon und pyridazinthionverbindungen mit pde iv inhibierender wirkung |
US5716954A (en) | 1991-10-09 | 1998-02-10 | Syntex U.S.A. Inc. | Benzopyridazinone and pyridopyridazinone compounds |
DE4237656A1 (de) | 1992-06-13 | 1993-12-16 | Merck Patent Gmbh | Benzimidazolderivate |
EP0666851A4 (en) | 1992-11-02 | 1995-08-30 | Merck & Co. Inc. | Substituted phthalazinones as nerotensin antagonists. |
US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
EP0634404A1 (en) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazin derivatives and their use as pesticides |
GB9314412D0 (en) | 1993-07-13 | 1993-08-25 | Rhone Poulenc Agriculture | New compositions of matter |
TW263498B (sl) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
JP3247540B2 (ja) | 1994-05-12 | 2002-01-15 | 株式会社日立製作所 | パケット化通信装置および切替え装置 |
US5466697A (en) | 1994-07-13 | 1995-11-14 | Syntex (U.S.A.) Inc. | 8-phenyl-1,6-naphthyridin-5-ones |
IL115889A0 (en) | 1994-11-14 | 1996-01-31 | Rohm & Haas | Pyridazinones and their use as fungicides |
JPH08337583A (ja) * | 1995-04-13 | 1996-12-24 | Takeda Chem Ind Ltd | 複素環化合物およびその製造法 |
US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
WO1997001551A1 (en) | 1995-06-26 | 1997-01-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole compounds and pharmaceutical compositions |
IL118631A (en) | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
AU723064B2 (en) | 1995-08-25 | 2000-08-17 | Dow Agrosciences Llc | Compositions having synergistic fungitoxic effects |
ES2182108T3 (es) | 1996-09-13 | 2003-03-01 | Mitsubishi Pharma Corp | Compuestos de tienotriazolodiazepina y usos medicinales de los mismos. |
US5855654A (en) | 1997-01-30 | 1999-01-05 | Rohm And Haas Company | Pyridazinones as marine antifouling agents |
EP0984961B1 (en) | 1997-04-01 | 2001-06-20 | AstraZeneca AB | Novel pyridine derivatives and pharmaceutical compositions containing them |
US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
PT1043317E (pt) | 1997-11-19 | 2009-05-11 | Kowa Co | Novos derivados de piridazina e fármacos que os contêm como ingrediente activo |
AU1791699A (en) | 1997-12-05 | 1999-06-28 | Astrazeneca Uk Limited | Novel compounds |
EP0934933A1 (en) | 1998-02-06 | 1999-08-11 | Byk Gulden Lomberg Chemische Fabrik GmbH | Phthalazinones |
TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
US6365589B1 (en) * | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
JP3910365B2 (ja) | 1998-07-16 | 2007-04-25 | 塩野義製薬株式会社 | 抗腫瘍活性を有するピリミジン誘導体 |
US6271380B1 (en) * | 1998-12-30 | 2001-08-07 | Dupont Pharmaceuticals Company | 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands |
CN1297916A (zh) | 1999-11-26 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人含溴基结构域的蛋白95和编码这种多肽的多核苷酸 |
DE10010423A1 (de) | 2000-03-03 | 2001-09-06 | Bayer Ag | Substituierte 2,5-Dimethyldihydropyridazinone und ihre Verwendung |
CN1315397A (zh) | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人溴基结构域10和编码这种多肽的多核苷酸 |
WO2002001935A1 (en) | 2000-07-04 | 2002-01-10 | Robert John Eyre | Harvesting machine |
JP2003313169A (ja) | 2002-04-19 | 2003-11-06 | Otsuka Chemical Holdings Co Ltd | 4,4−ジフルオロ−3−ブテニル化合物及び農園芸用殺虫・殺ダニ剤 |
ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
CN100348599C (zh) * | 2002-06-06 | 2007-11-14 | 卫材R&D管理有限公司 | 新的稠合咪唑衍生物 |
AU2003249539A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
EP1537098A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company LLC | Monocyclic derivatives as matrix metalloproteinase inhibitors |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
SE527371C2 (sv) * | 2003-04-24 | 2006-02-21 | Volvo Lastvagnar Ab | Hjulupphängning för fordon samt fordon försett med sådan hjulupphängning |
WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
EP1642898B1 (en) | 2003-06-27 | 2013-03-27 | Msd K.K. | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
US7226920B2 (en) | 2003-08-06 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Aminotriazole compounds useful as inhibitors of protein kinases |
CA2542047A1 (en) | 2003-10-20 | 2005-05-12 | Merck & Co., Inc. | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors |
SG115845A1 (en) | 2004-03-31 | 2005-10-28 | Univ Singapore | Modulation of trip-br function and method of treating proliferative disorders |
GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
CA2588949A1 (en) | 2004-11-30 | 2006-06-08 | Artesian Therapeutics, Inc. | Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure |
EP1820797A4 (en) | 2004-12-01 | 2009-10-28 | Banyu Pharma Co Ltd | SUBSTITUTED PYRIDONE DERIVATIVE |
US7994325B2 (en) | 2005-03-14 | 2011-08-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
US8044042B2 (en) | 2005-05-30 | 2011-10-25 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and medicinal use thereof |
WO2007008145A1 (en) | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
WO2007008144A1 (en) | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
US7915267B2 (en) | 2005-10-28 | 2011-03-29 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof |
EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
PL2069312T3 (pl) | 2006-07-25 | 2013-03-29 | Cephalon Inc | Pochodne pirydazynonu |
US20080119457A1 (en) | 2006-08-24 | 2008-05-22 | Serenex, Inc. | Benzene, Pyridine, and Pyridazine Derivatives |
US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
CA2669399A1 (en) | 2006-11-13 | 2008-05-29 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Brd2ブロモドメイン結合剤 |
EP2183228B1 (en) | 2007-07-26 | 2014-08-20 | Vitae Pharmaceuticals, Inc. | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 |
CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
EP2426109B1 (en) | 2007-10-23 | 2013-12-18 | F. Hoffmann-La Roche AG | Novel kinase inhibitors |
WO2009054790A1 (en) | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
JP5451752B2 (ja) | 2008-05-01 | 2014-03-26 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
CA2722427A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
AU2009274567B2 (en) | 2008-07-25 | 2013-04-04 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
CN102292323B (zh) | 2008-11-20 | 2014-12-24 | 默沙东公司 | 芳基甲基苯并喹唑啉酮 m1受体正向变构调节剂 |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
US20100331320A1 (en) | 2009-04-30 | 2010-12-30 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
ES2564318T3 (es) | 2009-11-05 | 2016-03-21 | Glaxosmithkline Llc | Inhibidor de bromodominio de benzodiazepina |
WO2011054851A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Novel process |
GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
AU2010314395B2 (en) | 2009-11-05 | 2015-04-09 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
US20130061612A1 (en) | 2009-11-11 | 2013-03-14 | E.I. Du Pont De Nemours And Company | Refrigerant storage in secondary loop refrigeration systems |
HUE031073T2 (en) * | 2010-05-14 | 2017-06-28 | Dana Farber Cancer Inst Inc | Thieno triazolo-diazepine compounds for the treatment of neoplasia |
ES2526671T3 (es) * | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2013043553A1 (en) * | 2011-09-22 | 2013-03-28 | Glaxosmithkline Llc | Pyrrolopyridinone compounds and methods for treating hiv |
WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
MX2014012635A (es) * | 2012-04-20 | 2015-05-15 | Abbvie Inc | Derivados de isoindolona. |
EP2858982A4 (en) * | 2012-06-12 | 2015-11-11 | Abbvie Inc | PYRIDINONE AND PYRIDAZINONE DERIVATIVES |
CN105518007A (zh) * | 2013-06-28 | 2016-04-20 | 艾伯维公司 | 布罗莫结构域抑制剂 |
-
2011
- 2011-12-30 WO PCT/CN2011/002224 patent/WO2013097052A1/en active Application Filing
-
2012
- 2012-11-12 UA UAA201408584A patent/UA111770C2/uk unknown
- 2012-12-11 PT PT128635992T patent/PT2797918T/pt unknown
- 2012-12-11 ES ES12863599.2T patent/ES2665890T3/es active Active
- 2012-12-11 BR BR112014016233A patent/BR112014016233B1/pt active IP Right Grant
- 2012-12-11 ME MEP-2018-64A patent/ME03028B/me unknown
- 2012-12-11 RU RU2018107716A patent/RU2671571C1/ru active
- 2012-12-11 KR KR1020147021371A patent/KR102008975B1/ko active IP Right Grant
- 2012-12-11 AU AU2012361967A patent/AU2012361967B2/en active Active
- 2012-12-11 LT LTEP12863599.2T patent/LT2797918T/lt unknown
- 2012-12-11 HU HUE12863599A patent/HUE038391T2/hu unknown
- 2012-12-11 SI SI201231242T patent/SI2797918T1/sl unknown
- 2012-12-11 NO NO12863599A patent/NO2797918T3/no unknown
- 2012-12-11 EP EP12863599.2A patent/EP2797918B1/en active Active
- 2012-12-11 CA CA2859619A patent/CA2859619C/en active Active
- 2012-12-11 DK DK12863599.2T patent/DK2797918T3/en active
- 2012-12-11 WO PCT/CN2012/086357 patent/WO2013097601A1/en active Application Filing
- 2012-12-11 CN CN201280070860.1A patent/CN104136435B/zh active Active
- 2012-12-11 MX MX2014008143A patent/MX341740B/es active IP Right Grant
- 2012-12-11 JP JP2014549331A patent/JP6117238B2/ja active Active
- 2012-12-11 RS RS20180251A patent/RS56978B1/sr unknown
- 2012-12-11 EP EP17195000.9A patent/EP3360874A1/en not_active Withdrawn
- 2012-12-11 SG SG11201403717WA patent/SG11201403717WA/en unknown
- 2012-12-11 CN CN201710228946.7A patent/CN106986872B/zh active Active
- 2012-12-11 PL PL12863599T patent/PL2797918T3/pl unknown
- 2012-12-11 RU RU2014131378A patent/RU2647592C2/ru active
- 2012-12-11 PE PE2014001049A patent/PE20142340A1/es active IP Right Grant
- 2012-12-28 UY UY0001034559A patent/UY34559A/es active IP Right Grant
- 2012-12-28 AR ARP120105053A patent/AR089527A1/es active IP Right Grant
- 2012-12-28 TW TW101151266A patent/TWI602815B/zh active
-
2013
- 2013-03-14 US US13/828,285 patent/US9296741B2/en active Active
-
2014
- 2014-06-23 ZA ZA2014/04616A patent/ZA201404616B/en unknown
- 2014-06-25 PH PH12014501469A patent/PH12014501469A1/en unknown
- 2014-06-26 GT GT201400133A patent/GT201400133A/es unknown
- 2014-06-26 DO DO2014000152A patent/DOP2014000152A/es unknown
- 2014-06-27 CL CL2014001752A patent/CL2014001752A1/es unknown
- 2014-06-29 IL IL233454A patent/IL233454A/en active IP Right Grant
- 2014-07-10 CR CR20140332A patent/CR20140332A/es unknown
- 2014-07-24 CO CO14160451A patent/CO7020912A2/es unknown
- 2014-07-29 EC ECIEPI201411359A patent/ECSP14011359A/es unknown
-
2015
- 2015-05-04 HK HK15104242.1A patent/HK1203508A1/xx unknown
- 2015-05-05 HK HK15104248.5A patent/HK1203511A1/xx unknown
-
2016
- 2016-01-28 US US15/008,994 patent/US20160143916A1/en not_active Abandoned
-
2017
- 2017-03-21 JP JP2017053992A patent/JP6371430B2/ja active Active
- 2017-08-25 AU AU2017219100A patent/AU2017219100C1/en active Active
-
2018
- 2018-02-27 HR HRP20180357TT patent/HRP20180357T1/hr unknown
- 2018-02-28 CY CY20181100249T patent/CY1120287T1/el unknown
- 2018-06-19 US US16/012,379 patent/US20180296566A1/en not_active Abandoned
- 2018-07-11 JP JP2018131296A patent/JP2018172428A/ja active Pending
- 2018-10-23 RU RU2018137194A patent/RU2018137194A/ru not_active Application Discontinuation
-
2019
- 2019-01-17 HK HK19100847.4A patent/HK1258414A1/zh unknown
- 2019-06-05 AU AU2019203939A patent/AU2019203939A1/en not_active Abandoned
-
2020
- 2020-08-18 US US16/996,090 patent/US20210236508A1/en not_active Abandoned
-
2022
- 2022-02-14 UY UY0001039630A patent/UY39630A/es not_active Application Discontinuation
- 2022-03-25 AR ARP220100723A patent/AR125222A2/es unknown
- 2022-06-30 US US17/810,313 patent/US20230158039A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2797918T1 (sl) | Inhibitorji bromodomene | |
US11931363B2 (en) | Triazolopyrimidine compounds and uses thereof | |
AU2013207205B2 (en) | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of Hepatitis B | |
JP2015503529A5 (sl) | ||
JP2017532360A5 (sl) | ||
RU2015143191A (ru) | Дигидропирролопиридиновые ингибиторы бромодоменов | |
AU2011298844B2 (en) | Substituted imidazopyridazines | |
JP2021138718A (ja) | 統合ストレス経路のモジュレーター | |
JP2016522246A5 (sl) | ||
JP2017522346A5 (sl) | ||
HRP20130106T1 (hr) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
RU2009125897A (ru) | Ингибиторы фосфоинозитид-3-киназы и способы их применения | |
WO2012000304A1 (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
RU2017104510A (ru) | Соединения, активные по отношению к бромодоменам | |
JP2013523891A5 (sl) | ||
JP2016513660A5 (sl) | ||
JP2009513575A5 (sl) | ||
JP2016528298A5 (sl) | ||
JP2013510876A5 (sl) | ||
JP2016516724A5 (sl) | ||
RU2015143717A (ru) | 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия | |
WO2014147586A1 (en) | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh | |
JP2018528181A5 (sl) | ||
KR20220028075A (ko) | 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도 | |
JP2017501983A5 (sl) |